KR100812968B1 - A study of purifying hunman inner body with natural herbal plants - Google Patents
A study of purifying hunman inner body with natural herbal plants Download PDFInfo
- Publication number
- KR100812968B1 KR100812968B1 KR1020060125361A KR20060125361A KR100812968B1 KR 100812968 B1 KR100812968 B1 KR 100812968B1 KR 1020060125361 A KR1020060125361 A KR 1020060125361A KR 20060125361 A KR20060125361 A KR 20060125361A KR 100812968 B1 KR100812968 B1 KR 100812968B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- delete delete
- solid
- composition
- test
- Prior art date
Links
- 239000000284 extract Substances 0.000 claims abstract description 96
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 239000007787 solid Substances 0.000 claims abstract description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000843 powder Substances 0.000 claims abstract description 33
- 230000000391 smoking effect Effects 0.000 claims abstract description 31
- 239000000047 product Substances 0.000 claims abstract description 28
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 21
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 239000006228 supernatant Substances 0.000 claims abstract description 18
- 239000004615 ingredient Substances 0.000 claims abstract description 16
- 239000008213 purified water Substances 0.000 claims abstract description 16
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract 3
- 230000002829 reductive effect Effects 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 32
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 21
- 241000411851 herbal medicine Species 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 12
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 12
- 229940010454 licorice Drugs 0.000 claims description 12
- 231100000331 toxic Toxicity 0.000 claims description 12
- 230000002588 toxic effect Effects 0.000 claims description 12
- 244000025254 Cannabis sativa Species 0.000 claims description 10
- 240000006079 Schisandra chinensis Species 0.000 claims description 10
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 10
- 241001107116 Castanospermum australe Species 0.000 claims description 9
- 235000021279 black bean Nutrition 0.000 claims description 9
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 5
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 5
- 235000013527 bean curd Nutrition 0.000 claims description 5
- 244000061176 Nicotiana tabacum Species 0.000 claims description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 241000195493 Cryptophyta Species 0.000 claims description 2
- 239000000575 pesticide Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 241000205585 Aquilegia canadensis Species 0.000 claims 5
- 241000365112 Monsonia angustifolia Species 0.000 claims 1
- 241000270708 Testudinidae Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 21
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 abstract description 6
- 235000018958 Gardenia augusta Nutrition 0.000 abstract description 5
- 235000010469 Glycine max Nutrition 0.000 abstract description 5
- 244000068988 Glycine max Species 0.000 abstract description 5
- 240000000691 Houttuynia cordata Species 0.000 abstract description 5
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract description 5
- 241001499733 Plantago asiatica Species 0.000 abstract description 5
- 244000275701 Geranium nepalense Species 0.000 abstract description 4
- 244000046146 Pueraria lobata Species 0.000 abstract description 4
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 4
- 235000002594 Solanum nigrum Nutrition 0.000 abstract description 4
- 244000061457 Solanum nigrum Species 0.000 abstract description 4
- 244000167230 Lonicera japonica Species 0.000 abstract description 3
- 235000017617 Lonicera japonica Nutrition 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 235000005903 Dioscorea Nutrition 0.000 abstract 3
- 244000281702 Dioscorea villosa Species 0.000 abstract 3
- 235000000504 Dioscorea villosa Nutrition 0.000 abstract 3
- 235000004879 dioscorea Nutrition 0.000 abstract 3
- 244000237330 gutta percha tree Species 0.000 abstract 3
- 239000000706 filtrate Substances 0.000 abstract 2
- 238000013019 agitation Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 66
- 238000000855 fermentation Methods 0.000 description 63
- 230000004151 fermentation Effects 0.000 description 63
- 241001465754 Metazoa Species 0.000 description 45
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 38
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 38
- 229960002715 nicotine Drugs 0.000 description 37
- 239000000126 substance Substances 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 235000013305 food Nutrition 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 238000011084 recovery Methods 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 241000233866 Fungi Species 0.000 description 17
- 241000208125 Nicotiana Species 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 239000000779 smoke Substances 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 239000011269 tar Substances 0.000 description 13
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000033001 locomotion Effects 0.000 description 12
- FLAQQSHRLBFIEZ-UHFFFAOYSA-N N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine Chemical compound O=NN(C)CCCC(=O)C1=CC=CN=C1 FLAQQSHRLBFIEZ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 235000019504 cigarettes Nutrition 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 231100000614 poison Toxicity 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 230000002000 scavenging effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000004378 Glycyrrhizin Substances 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000009395 breeding Methods 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 7
- 229960004949 glycyrrhizic acid Drugs 0.000 description 7
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 7
- 235000019410 glycyrrhizin Nutrition 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 150000004005 nitrosamines Chemical class 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241001570521 Lonicera periclymenum Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010033799 Paralysis Diseases 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 230000000711 cancerogenic effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 6
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
- 238000010953 Ames test Methods 0.000 description 5
- 231100000039 Ames test Toxicity 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 208000037386 Typhoid Diseases 0.000 description 5
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 5
- 231100000315 carcinogenic Toxicity 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 229940097043 glucuronic acid Drugs 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 201000008297 typhoid fever Diseases 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010060891 General symptom Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 4
- -1 isoflavone glycosides Chemical class 0.000 description 4
- 235000008696 isoflavones Nutrition 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 231100000243 mutagenic effect Toxicity 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- 238000007034 nitrosation reaction Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000001972 Gardenia jasminoides Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000012159 carrier gas Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000004459 forage Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940051810 licorice root extract Drugs 0.000 description 3
- 235000020725 licorice root extract Nutrition 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002231 macronucleus Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 231100000299 mutagenicity Toxicity 0.000 description 3
- 230000007886 mutagenicity Effects 0.000 description 3
- 230000009935 nitrosation Effects 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229960001789 papaverine Drugs 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000001034 respiratory center Anatomy 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229960003654 desoxycortone Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000004401 flow injection analysis Methods 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229930182489 iridoid glycoside Natural products 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940005121 nicotine 4 mg Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910017464 nitrogen compound Inorganic materials 0.000 description 2
- 150000002830 nitrogen compounds Chemical class 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 229920003175 pectinic acid Polymers 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NIZFPXZQERMCLE-KVFWHIKKSA-N (e)-1-[4-[(2s,3r,4s,5s,6r)-3-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@](O)(CO)CO1)O)O)CO)C(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 NIZFPXZQERMCLE-KVFWHIKKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- IRJNJBIOUYJBHG-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCCC1C1=CC=CN=C1 IRJNJBIOUYJBHG-UHFFFAOYSA-N 0.000 description 1
- ZJOFAFWTOKDIFH-JTQLQIEISA-N 3-[(2s)-1-nitroso-3,6-dihydro-2h-pyridin-2-yl]pyridine Chemical compound O=NN1CC=CC[C@H]1C1=CC=CN=C1 ZJOFAFWTOKDIFH-JTQLQIEISA-N 0.000 description 1
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010001914 Amblyopia tobacco Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- 244000105059 Geranium thunbergii Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 244000010922 Plantago major Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- CGMGCGYLRFAMQF-CHHVJCJISA-N Puerarol Natural products O=C1Oc2c(-c3oc4c(c13)ccc(O)c4)cc(C/C=C(\CC/C=C(\C)/C)/C)c(O)c2 CGMGCGYLRFAMQF-CHHVJCJISA-N 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 description 1
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 description 1
- QCTMYNGDIBTNSK-UHFFFAOYSA-N Solasonin Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O QCTMYNGDIBTNSK-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010068887 Tobacco poisoning Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- BLRFKPWRSOZROE-UHFFFAOYSA-N beta-Solamargin Natural products CC1CCC2(NC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(COC8OC(C)C(OC9OC(C)C(O)C(O)C9O)C(O)C8O)C(O)C(O)C7O BLRFKPWRSOZROE-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007052 brain toxicity Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 231100000976 cerebrotoxicity Toxicity 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229930008677 glyco alkaloid Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- VMMVZVPAYFZNBM-CMDYPFMGSA-N isoliquiritin apioside Natural products O=C(/C=C/c1ccc(O[C@H]2[C@@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)cc1)c1c(O)cc(O)cc1 VMMVZVPAYFZNBM-CMDYPFMGSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- AMBQHHVBBHTQBF-DLXIZZNVSA-N methyl 6-hydroxy-7-methyl-1-[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Chemical compound C12C(C)C(O)CC2C(C(=O)OC)=COC1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O AMBQHHVBBHTQBF-DLXIZZNVSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- XKABJYQDMJTNGQ-VIFPVBQESA-N n-nitrosonornicotine Chemical compound O=NN1CCC[C@H]1C1=CC=CN=C1 XKABJYQDMJTNGQ-VIFPVBQESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- AXFBAIOSECPASO-UHFFFAOYSA-N pentacyclo[6.6.2.02,7.04,16.011,15]hexadeca-1(14),2(7),3,5,8(16),9,11(15),12-octaene Chemical compound C1=C(C=C23)C4=C5C3=CC=CC5=CC=C4C2=C1 AXFBAIOSECPASO-UHFFFAOYSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- BIMWFUACEQGSPS-UHFFFAOYSA-N solamargin Natural products CC1CCC2(NC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(COC8OC(C)C(O)C(O)C8O)C(O)C(O)C7OC9OC(C)C(O)C(O)C9O BIMWFUACEQGSPS-UHFFFAOYSA-N 0.000 description 1
- 229930188627 soysaponin Natural products 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000029517 toxic amblyopia Diseases 0.000 description 1
- 231100001234 toxic pollutant Toxicity 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- QCTMYNGDIBTNSK-XEAAVONHSA-N α-Solamarine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QCTMYNGDIBTNSK-XEAAVONHSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 비장 세포에 의한 증식효과를 나타낸 것이고Figure 1 shows the proliferation effect by spleen cells
도 2는 2-Aminofluorene(2-AF)의 돌연변이 유발력 결과를 나타낸 것이고Figure 2 shows the mutagenicity results of 2-Aminofluorene (2-AF)
도 3은 담배의 타르 중에서 NNN, NAT, NNK, B(a)P의 정량분석 결과를 나타낸 것이다.Figure 3 shows the results of quantitative analysis of NNN, NAT, NNK, B (a) P in the tar of tobacco.
본 발명은 통상적인 흡연관련 생약조성물을 개량하여 통상적인 조성물과 다른 새로운 조성물을 제안함으로써 흡연으로 인한 인체 내의 유독성분 제거에 유효한 효능이 보다 좋은 한약재 생약 조성물을 얻을 수 있도록 함과 동시에 위 조성물을 이용하여 생약을 용이하게 제조할 수 있는 방법을 제공할 수 있도록 한 것이다. The present invention improves the conventional smoking-related herbal composition to propose a new composition different from the conventional composition to obtain a herbal composition with better efficacy in removing toxic components in the human body due to smoking and at the same time using the above composition It is to be able to provide a method for easily manufacturing a herbal medicine.
일반적으로 흡연으로 인한 인체 내의 감소란 생체 내의 세포에서 유독한 물질을 무독한 물질로 바꾸는 것을 말하며 즉, 생체에 있어서 작용이 적은 구조 또는 배설되기 쉬운 구조로 바꾸는 일정한 생화학 반응을 말한다.In general, a decrease in the human body due to smoking refers to the conversion of a toxic substance into a non-toxic substance in cells in a living body, that is, a constant biochemical reaction in which the body converts a structure that is less actionable or easy to excrete.
생명을 둘러싸고 있는 환경은 산소와 같은 간단한 분자에서 단백질과 같은 큰 분자에 이르기까지 다양하다. 이들 물질은 적당량이면 어느 것이나 모두 세포에 필요하거나 해가 없는 것들이다. 그러나 적당량 이상이 있으면 세포의 정상적인 기능을 저해하게 된다.The environment that surrounds life varies from simple molecules like oxygen to large molecules like proteins. All of these substances, if appropriate, are needed or harmless to the cells. However, if the amount is above a certain amount will inhibit the normal function of the cell.
어떤 물질이 세포에 있어 유해하게 되는 양은 생물의 종류에 따라 다르지만, 동종의 생물 세포에 있어서는 거의 동등하다.The amount at which a substance is harmful to cells depends on the type of organism, but is nearly equal for all kinds of biological cells.
해독 요법은 인체 내에서부터 몸에 해로운 독소를 해독하는 치료법이다.Detoxification therapy is a treatment that detoxifies harmful toxins from inside the body.
사람들은 일상 생활 속에서 매일 수천 가지의 독성 화학 물질과 물, 흙의 오염물질에 노출되어 있다. 이러한 물질들은 자체로써 면역, 신경 독성, 호르몬 부작 용, 정신적 문제, 심지어는 암 등 여러 가지 증상을 야기한다.People are exposed to thousands of toxic chemicals and pollutants of water and soil every day in their daily lives. These substances themselves cause a number of symptoms, including immunity, neurotoxicity, hormonal side effects, mental problems, and even cancer.
이렇게 많은 위험요소 인자들에 노출된 상태에서도 인체 내에는 신장과 간, 소변, 대변, 호흡을 통해 독성 물질과 노폐물을 배출시키는 자연적인 작용이 이루어지고 있다. Even when exposed to so many risk factors, the human body has a natural effect of releasing toxic substances and waste products through the kidneys, liver, urine, feces and respiration.
그러나 산업혁명 이후 각종 화학 물질, 살충제, 각종 약제, 식품 첨가제, 중금속, 마취제, 각종 약물 등과 알코올이나 담배, 카페인 등의 합법화된 물질들, 그리고 불법 마약류 등 각종 물질 등에 의해 매우 많은 량이 노출되어 있어 자연적 배설 과정의 기능에는 한계가 있다.Since the Industrial Revolution, however, many chemicals, insecticides, various drugs, food additives, heavy metals, anesthetics, various drugs, and legal substances such as alcohol, tobacco, caffeine, and various substances such as illegal drugs are exposed. There is a limit to the function of the excretion process.
오늘날 현대인들은 이전 세대보다 훨씬 많은 양의 화학 물질에 노출되고 있으며 질병의 상태 또한 복잡해지고 만성화되어 있으며 이로 인하여 면역 기능저하, 신경 질환, 호르몬 기능 저하, 정신 질환, 암 등이 발생하고 있는 것이다.Today's people are exposed to a much larger amount of chemicals than their predecessors, and the condition of the disease is complicated and chronic, resulting in immunocompromised, neurological, hormonal, mental and cancer diseases.
따라서 종래에도 상기에서 노출된 위험요소 인자들에 대하여 효과적인 독성감소 및 방어능력 향상에 기여할 수 있는 각종 유용성 화합물에 대한 많은 연구가 실시되고 있으나 괄목한 만한 기능성 첨가물의 개발이 이루어지지 못하고 있는 실정이다.Therefore, many studies have been conducted on various useful compounds that may contribute to effective toxicity reduction and defense ability protection against the exposed risk factors, but the development of remarkable functional additives has not been made.
또한, 사람들의 건강에 피해를 주는 많은 물질과 요소들이 있지만 그 중에서 가장 많은 피해를 주는 것이 담배다. 담배는 현시대에서 가장 큰 예방 가능한 사망원인이다.In addition, there are many substances and elements that harm people's health, but the most damaging is tobacco. Tobacco is the biggest cause of death in the modern age.
흡연과 질병의 관련성에 대한 연구는 1900년대 중반 이후 집중적으로 연구되기 시작했으며, 흡연으로 인한 폐암을 비롯한 각종 질병의 발생증가와 다른 건강장애에 대한 증거가 지속적으로 쌓이고 있다.The research on the association between smoking and disease has been intensively studied since the mid-1900s, and there is a continuous evidence of increasing incidence of various diseases including lung cancer caused by smoking and other health disorders.
실제로 담배연기 속에서 일찍이 약 4,000 여종의 성분을 찾아냈으며, 현재는 주류연에 포함된 성분이 10만 종이 넘을 것으로 추정하고 있으며 그 중에서 니코틴은 신경계에서의 작용을 보면, 자율신경계 내의 모든 니코틴성 수용체와 결합하여 모든 교감, 부교감 신경에 흥분작용을 일으킨다.In fact, about 4,000 kinds of components were found in cigarette smoke as early as present, and it is estimated that there are more than 100,000 kinds of components in mainstream smoke. Among them, nicotine shows the effects of all nicotinic receptors in autonomic nervous system. In combination it causes excitement in all sympathetic, parasympathetic nerves.
그러나 이러한 흥분작용은 지속적으로 일어나지 않으며 대량의 니코틴 공급시에는 흥분작용의 시간이 매우 짧아지고 중추신경계에 대해서 니코틴은 자율신경계에서와 마찬가지로 처음에 흥분시켰다가 나중에는 마비시킨다.However, this excitement does not occur continuously, and when a large amount of nicotine is supplied, the time of excitation is very short, and for the central nervous system, nicotine is initially excited as in the autonomic nervous system and later paralyzed.
즉 척수의 반사흥분성이 증가하고, 연수의 각 중추(미주신경중추, 호흡중추 등)가 흥분되어 맥박이 느려지고 호흡이 빨라지게 되며 진전(tremor)이 나타나고 이어서 전신의 경련이 일어난다.That is, the reflex excitability of the spinal cord is increased, each center of the training (excited nerve center, respiratory center, etc.) is excited to slow the pulse, faster breathing, tremor appears, and then the whole body spasms.
이와 같은 흥분작용에 이어 마비기에 들어가므로 끝내는 호흡중추 및 말초호흡근 마비로 사망할 수도 있으며 한꺼번에 과량의 담배를 피울 경우 사망하게 되는 원인이 여기에 있는 것이다.Following the excitement action, the paralysis enters the end of the respiratory center and peripheral respiratory paralysis may die, and if you smoke too much at once is the cause of death.
순환계에서 혈관 및 혈압은 혈관운동 중추 및 교감신경계의 작용이 우세하게 나타나 혈관은 수축되고 혈압이 상승하나 점차 시간이 흐름에 따라 혈압은 다시 하강하게 되며 이 때문에 흡연자들은 보통 맥박이 빠르게 되며 특히 심혈관 계통에 질환이 있는 사람들이 흡연을 하게 되면 혈관이 수축되어 좁아져 혈관을 더욱 악화시킴으로 심근경색 또는 허혈증세를 나타나게 된다.In the circulatory system, blood vessels and blood pressure predominantly affect the function of the vascular movement center and sympathetic nervous system, which causes blood vessels to contract and increase blood pressure, but as time passes, the blood pressure decreases again. When people with the disease smoke, blood vessels shrink and narrow, which makes the blood vessels worse, resulting in myocardial infarction or ischemia.
또한, 니코틴은 호흡중추와 호흡근의 마비, 신체 내의 각종 분비선의 항진과 억제, 결막염, 시신경의 위축, 시신경절의 퇴행변성이 나타나서 소위 담배약시(Tobacco amblyopia)를 야기하며, 소화기 계통에는 부교감 신경을 자극하여 장운동을 증가시키고 오심, 구토, 심하면 설사를 초래하며 니코틴이 체중 1㎏당 1㎎이 되면 사망한다고 알려져 있으며 혈중 부신피질호르몬, 유리지방산 및 항이뇨호르몬을 증강하고 혈당을 상승시킨다.Nicotine also causes paralysis of the respiratory center and respiratory muscles, hyperactivity and inhibition of various glands in the body, conjunctivitis, atrophy of the optic nerve, and degeneration of the optic ganglia resulting in so-called tobacco amblyopia and stimulating parasympathetic nerves in the digestive system. Increasing bowel movements, nausea, vomiting, severe diarrhea, and nicotine is known to die when 1mg per 1kg of body weight, corticosteroids, free fatty acids and antidiuretic hormones in the blood to increase blood sugar.
또한, 니코틴은 니코틴유도체(nicotine derived nitros amine)에 의해 매우 강력한 발암물질로 작용하여 흡연으로 인한 폐암 환자는 전 세계적으로 매년 수억 에 이르고 있으며, 1956년 Magee와 Barnes는 니트로소디메틸아민(N'-Nitrosodimethylamine :NDMA)이 쥐에게서 매우 강력한 간암유발물질임을 증명(Magee,P. N., and Barnes, J. M. (1956) Br. J. Cancer, 10, 114-122) 하였으며, 그 후에는 약 200개 이상의 N-nitrosamine중에서 발암성을 지닌 화합물이 30종 이상 확인되었다.In addition, nicotine acts as a very potent carcinogen by nicotine derived nitros amine, which has resulted in hundreds of millions of lung cancer patients worldwide every year from smoking, and in 1956 Magee and Barnes reported nitrosodimethylamine (N'-). Nitrosodimethylamine (NDMA) proved to be a very potent liver cancer-causing agent in mice (Magee, PN, and Barnes, JM (1956) Br. J. Cancer, 10, 114-122), after which more than 200 N-nitrosamines More than 30 compounds with carcinogenicity were identified.
그리고 Smith등은 여러 가지 나이트로 사민이 니코틴으로부터 형성되어 진다는 것을 보여주었고, Hecht는 NNK, NNA, NNN등 많은 다른 물질들이 니코틴으로부터 형성되어 진다는 것을 증명하였다. Smith and others showed that various nitrosamines were formed from nicotine, and Hecht demonstrated that many other substances, such as NNK, NNA, and NNN, were formed from nicotine.
그리고 타르는 담배를 피우는 사람들은 흔히들 담배맛이 있다고 하는데 이것은 담배마다 독특한 타르 향을 즐기는 것으로 타르는 목초를 태울 때 흐르는 진 같은 것을 말하는데 담배도 건조된 풀잎이므로 타르가 나온다. And people who smoke tar are often said to have a taste of tobacco, which means that each cigarette enjoys a unique tar scent, such as gin that flows when burning burning grass.
흡연이 몸에 해롭다고 하는 것은 바로 타르가 몸에 해롭다는 말과 같은데 담배에서 가장 해로운 성분은 타르라고 말할 수 있다.The fact that smoking is harmful to the body is the same as saying that tar is harmful to the body. The most harmful ingredient in cigarettes is tar.
타르는 암 발생의 가장 중요한 역할을 담당하며, 담배 속에는 1,200여종의 암 유발 인자를 포함하고 있는데 이 중 대부분이 타르에 속하는 물질들이다. 타르 속에 있는 대부분의 발암성 물질은 단백질성 질소형태이며 이러한 질소 성분은 호 흡기계뿐 아니라 신체 여러 부위에서 암을 유발하며 특히 오줌 속으로 배출되므로 방광암의 발생률을 높이게 된다. 그럼에도, 담배 애호가는 끽연의 습관을 끊는다는 일은 쉬운 일이 아니며, 또 끽연을 계속하면서 흡연으로 인한 각종 질병들을 미리 방지하는 실시 용이한 수단과 방법도 없었다.Tar plays the most important role in cancer, and cigarettes contain more than 1,200 cancer-causing agents, most of which belong to tar. Most of the carcinogenic substances in tar are proteinaceous nitrogen, which causes cancer not only in the respiratory system but also in many parts of the body, especially in the urine, thus increasing the incidence of bladder cancer. Nevertheless, it is not easy for a cigarette lover to quit smoking habits, and there is no easy means and method to prevent various diseases due to smoking while continuing to smoke.
본 발명은 흡연으로 인해 축적되는 인체 내의 유독성분을 제거 또는 감소 또는 해독할 수 있는 생약 제안에 그 기술적 과제를 두고 발명한 것으로, 본 발명에서는 한국 및 중국에서 오랫동안 한약재 및 식용으로 사용되어 오고 있을 뿐만 아니라 담배의 독성(니코틴, 타르, 다이옥신 등)을 감소하는 효능을 가졌음이 입증된 천연 생약제 중 삼백초, 이질풀, 흑두, 차전초, 용규, 갈근, 두충, 토복령, 산약,인동덩굴, 감초, 치자, 오미자를 주성분으로 하는 생약 조성물 및 그 제조방법을 제공하여 본 발명의 기술적 과제를 해결하고자 하는 것이다.
이를 보다 구체적으로 설명하면 다음과 같다.The present invention has been invented with the technical problem to propose a herbal medicine that can remove, reduce or detoxify toxic components in the human body accumulated due to smoking, and the present invention has been used as a herbal medicine and food for a long time in Korea and China. In addition, among natural herbal medicines that have been shown to reduce the toxicity of tobacco (nicotine, tar, dioxin, etc.), three hundred seconds, algae grass, black bean, chajeoncho, yonggyu, brown root, tofu, bokbokyeong, mountain medicine, honeysuckle, licorice, gardenia, It is intended to solve the technical problem of the present invention by providing a herbal composition and a method of manufacturing the main ingredient of Schisandra chinensis.
This will be described in more detail as follows.
삭제delete
삭제delete
본 발명은 이미 알려진 바와 같이 다양한 효능을 가진 삼백초, 이질풀, 흑두, 차전초, 용규, 갈근, 두충, 토복령, 산약, 인동덩굴, 감초, 치자, 오미자를 각각 1 내지 10 중량부로부터 얻은 성분을 함유하는 생약 조성물과 상기 조성물의 제조방법을 제공할 수 있도록 한 것인데, 아래에서는 먼저 위 천연 생약제의 성분과 통상적인 효능을 살핀 후 이 천연 생약제를 이용한 조성물 제조방법을 설명하기로 하나, 그 효능이 자명한 성분에 대한 설명은 생략하기로 한다.The present invention contains the ingredients obtained from 1 to 10 parts by weight, respectively, three hundred seconds, lichen grass, black bean, chajeoncho, yonggyu, brown root, tofu, Tobokyeong, powder, honeysuckle, licorice, gardenia, Schisandra chinensis, as known To provide a herbal composition and a method for preparing the composition, the following is a description of the method of preparing a composition using the natural herbal medicine, after first looking at the components and normal efficacy of the natural herbal medicine, but the efficacy is obvious A description of one component will be omitted.
삼백초 ( Houttuynia cordata thunb ( poly cordata Bueck )는 식물의 줄기와 잎을 주로 사용하며 주성분으로 메틸노닐케논 CH3(CH2)8COCH3(데카노일 아세트알데히드의 산화 생성물) 미르센(C10H16), 라우린 알데히드(C11H23CHO), 카프린알데히드(C9H19CHO), 카프르산이고 이 밖에도 다수의 성분과 잎에는 쿠에르시트린과 물에 풀리는 무기성분이 있으며 작용으로는 쿠에르시트린는 오줌내기작용(10만 배농도)과 강심작용이 있고 대장균, 장티푸스균, 파라티푸스균, 적리균, 임균, 포도알균, 사상균에 대한 항균작용과 모세혈관 강화작용이 있으며, 데카노일 아세트알데히드는 비병원성 곰팡이는 물론 백선균, 무좀균 등에 대한 항균작용이 있으며 포도알균, 임균, 항산성균에도 억균작용이 있다. Three hundred seconds ( Houttuynia cordata thunb ( poly cordata Bueck ) mainly uses the stem and leaves of the plant, and the main components are methylnonylkenone CH 3 (CH 2 ) 8 COCH 3 (oxidation product of decanoyl acetaldehyde) myrcene (C 10 H 16 ), laurin aldehyde (C 11 H 23 CHO), caprinaldehyde (C 9 H 19 CHO), capric acid, and many other components and leaves contain quercitrin and minerals released in water. Tenfold concentration) and cardiac activity, and antibacterial and capillary potentiation effects against E. coli, typhoid, paratyphoid, erythropoietic, gonococcus, staphylococcus, and filamentous fungi. It has antimicrobial activity against Staphylococcus aureus, gonococcus, and acidophilic bacteria.
응용하는 곳은 전초는 염증약, 이뇨해독약으로 임질과 요도염, 방광염, 자궁염, 폐렴, 기관지염, 물 고임, 무좀치료, 탈 항, 악창, 풍악, 축농증 등에 쓰인다.Its applications are inflammatory drugs and diuretic poisoning drugs, which are used for gonorrhea, urethritis, cystitis, uteritis, pneumonia, bronchitis, water pooling, athlete's foot treatment, antidepressant, swelling, windworm, sinusitis.
이질풀(Geranium nepalense Sweet (G. thunbergii Siebold et Zuccarini )은 식물의 어린잎을 사용하며 주성분은 피로갈롤타닌, 몰식자산, 호박산, 쿠에르세틴과 그 배당체, 그리고 켐페롤과 켐페리트린 C27H30O14·3 1/2 H2O (켐페롤의 디람노시드)이 있으며, 다른 자료에 의하면 엘라그타닌의 한 종류인 게라닌을 주성분으로 한 타닌질이 있다. Geranium nepalense Sweet (G. thunbergii Siebold et Zuccarini ) uses the young leaves of plants, the main components of which are pyrogalloltanine, glutenous acid, succinic acid, quercetin and its glycosides, and camphorol and kemperitriline C 27 H 30 O 14 · 3 1/2 H 2 O (D'rhamnoside from Camperol), and other sources show tannins based on geranine, a type of ellagtanine.
삭제delete
주작용으로 전초의 물 추출액 또는 알코올 추출액은 장의 긴장도를 높인다. 설사멎이 작용은 비스무트 제제처럼 뚜렷하며 많은 양을 써도 부작용이 없고 밥맛을 떨어내지 않으며, 적리균, 장티푸스균, 대장균에 살균작용이 있다.As a main action, the water extract or alcohol extract of the outpost increases intestinal tension. Diarrhea is as clear as bismuth preparation, and no amount of side effects, even if you use a large amount of rice, do not lose the taste, bactericidal bacteria, typhoid fever, E. coli bactericidal action.
흑두 ( 黑豆 ) ( Glycine max (L.) Merrill)는 다른 이름으로는 서리태, 콩, 대두라고 부르며 성분으로는 씨에는 단백질이 36~45%, 기름이 17~22% 들어 있으며 이 밖에 트리테르페노이드사포닌, 질소화합물, 탄수화물, 사탕, 펙틴, 무기물과 비타민이 있다. Heukdu (黑豆) (Glycine max (L. ) Merrill) is another name in the seoritae, as called beans, soybean components has said protein is 36-45%, the oil contains 17-22% Other tree pepper Terre There are nooids saponins, nitrogen compounds, carbohydrates, candies, pectins, minerals and vitamins.
단백질의 80~90%는 필수 아미노산, 즉 아르기민, 메티오닌, 트레오닌, 류신, 이소류신, 발린 등으로 이루어져 있으며 인지질 함량으로 레시틴 1~3.5%, 케팔린 등이 있고 질소 화합물로는 아데닌, 구아닌, 콜린, 트리고넬린, 아미노산인 히스티딘이 있다.80 ~ 90% of protein consists of essential amino acids such as arginine, methionine, threonine, leucine, isoleucine, valine, etc.Phospholipid content includes
탄수화물은 거의 완전히 물에 풀리는 것들로 이루어졌으며, 그 가운데에는 3.3~13%는 사카로오스이다.Carbohydrates are made up almost completely of water, including 3.3-13% saccharose.
회분에는 K, Mg, Cu, Fe, Mn, Ni, Zn과 흔적의 Co 그리고 인산이 있고 비타민 A, B1, B2, D, E, K와 이소플라본 배당체인 다이아진과 헤니스틴, 로비닌 등이 들어 있다. The ash contains K, Mg, Cu, Fe, Mn, Ni, Zn and traces of Co and phosphoric acid, and vitamins A, B 1 , B 2 , D, E, K and isoflavone glycosides such as diazine, heistin, and rovinin. This contains.
작용하는 곳은 콩 사포닌은 지질대사에 활성이 있다. 콩에 들어 있는 레시틴은 물에 잘 풀리지 않는 지방질, 스테로이드 등을 유화시켜 물에 풀리게 하는 성질이 있으므로 동맥경화를 일으키는 주물질인 콜레스테롤의 양을 줄인다. Where it works, soy saponin is active in lipid metabolism. Lecithin in soybeans emulsify fats and steroids, which are not easily soluble in water, so that they are released in water, thereby reducing the amount of cholesterol, the main substance that causes atherosclerosis.
또한 레시틴은 몸안에서 콜린, 글리세로인산, 지방산 등으로 물 분해되므로 신경 인지질 대사 과정에 좋은 영향을 준다.Lecithin also breaks down the body into choline, glycophosphate, and fatty acids, which have a beneficial effect on neurophospholipid metabolism.
응용하는 곳으로 중추신경 계통을 자극하는 약제, 당뇨병과 광선병 치료 약품을 만드는 원료로 쓰며 위액의 지나친 분비, 급성 및 만성 전염성 질병, 장티푸스 등에 좋다. It is used as a raw material to make drugs that stimulate the central nervous system, drugs to treat diabetes and light diseases, and is good for excessive secretion of gastric juice, acute and chronic infectious diseases, and typhoid fever.
동의치료에서는 소염성 건위약, 소화약, 열내림약, 땀내기약으로 열병의 초기, 머리가 아프고 추울 때에 쓴다.In motion therapy, anti-inflammatory stomachache, digestive medicine, fever lowering medicine and sweating medicine are used in the early stages of fever and when the head is sore and cold.
차전초 ( Plantago asiatica L.(P.major L. var. asiatica Decne )는 전초를 꽃필 때 잎의 밑을 잘라서 햇볕에 말린 것을 사용하며 성분으로 잎에는 이리도이드 배당체인 아우쿠빈 (C15H24O9) 카탈폴과 플라보노이드인 폴란타기닌(스쿠텔라레인-7-글루코시드), 호모플란타기닌(히스피톨린-7-글루코시드)과 아피게닌, 루테올린, 네페틴, 6-옥시루테올린 배당체 및 우르솔산, 헨트리아콘탄 (C23H48), β-시토스테롤, 스티그마스테롤 및 β-시토스테롤의 팔미트산 에스테르가 있다. Chachocho ( Plantago asiatica L. (P.major L. var. asiatica Decne ) is used to cut the bottom of leaves and dry them in the sun.The leaves contain aquabin, an iridoid glycoside (C 15 H 24 O 9 ). Catalanpol and flavonoids, lantaginine (scutellalane-7-glucoside), homoplantaginine (hispitolin-7-glucoside) and apigenin, luteolin, nefetin, 6-oxyluteolin glycosides, and Ursolic acid, gentriacontane (C 23 H 48 ), palmitic acid esters of β-sitosterol, stigmasterol and β-sitosterol.
효소(에물신과 인베로틴)와 카로틴, 아스코르브산도 있고, 씨에는 아우쿠빈과 많은 점액이 있다.There are also enzymes (emulsine and inverotene), carotene and ascorbic acid, and seeds have acubin and a lot of mucus.
점액을 부분 물 분해하면 이당류 Ⅰ[O-β-D-크실로피라노실-(1→ 2)-D-크실로피라노오스], И[O-β-D-크실로피라노실-(1→4)-D-크실로피라노오스], Ⅲ[(-β- D-글루코피라노실-우론산-(1→5)-L-아라비노피라노오스)]이 생긴다. 이 밖에 플란테놀산, 호박산, 콜린, 아데닌, 비타민 A, B1이 있다.Partial hydrolysis of the mucus resulted in the disaccharide I [O-β-D-xyclopyranosyl- (1 → 2) -D-xyclopyranose], И [O-β-D-xyclopyranosyl- (1 → 4) -D-xyclopyranose] and III [(-β-D-glucopyranosyl-uronic acid- (1 → 5) -L-arabinopyranose)]. Others include planthenol acid, succinic acid, choline, adenine, vitamins A and B 1 .
전초에는 물에 풀리는 다당류가 있다. 다당류에는 회분이 28%까지 있으며, 전기투석하여도 약 절반밖에는 제거되지 않는다. 오랜 시간 정제하면 회분이 0.4~0.5%에 이른다. 다당류에는 80~82%의 펙틴산, 5~6%의 갈락토아라반, 4~5%의 갈락탄으로 이루어졌다. 펙틴산은 물 분해하면 갈락투론산이 78~83%, 갈락토오스, 아라비노오스, 람노오스, 적은양의 포도당, 크실로로스와 이 밖에 3개의 당이 생긴다. 즉 다당류는 모두 9개의 당과 무기물로 이루어졌다.Outposts have polysaccharides that are released in water. Polysaccharides contain up to 28% ash, and only about half are removed by electrodialysis. If refined for a long time, the ash reaches 0.4 ~ 0.5%. Polysaccharides consisted of 80-82% pectinic acid, 5-6% galactoaraban and 4-5% galactan. Pectinic acid produces 78-83% of galacturonic acid, galactose, arabinose, rhamnose, small amounts of glucose, xylose and three other sugars. In other words, the polysaccharide consists of all nine sugars and minerals.
작용하는 곳은 전초와 플란타긴은 동물실험에서 호흡중추에 작용하여 호흡을 느리고 깊게 한다. 또한 점막의 분비기능을 높여 기관지점막과 소화액의 분비를 늘린다. Where it works, outposts and planttagins act on the respiratory centers in animal experiments, slowing and deepening breathing. It also increases the secretion of mucous membranes, increasing the secretion of bronchial mucosa and digestive juices.
씨의 점액은 완화작용과 열내림 작용을 한다.Seed mucus is a relaxing and heat-lowering effect.
다당류 성분은 항염증작용, 상피화 촉진작용이 있다. Polysaccharide component is anti-inflammatory, epithelialization promoting action.
전초추출액은 동물실험에서 곪은 상처에 대한 항염증작용과 상피화 촉진작용을 한다.Outpost extracts have anti-inflammatory and epithelial activity in small wounds in animal experiments.
다당류를 흰쥐에게 1내지 3g/kg, 개에게 2내지 5g/kg씩 14일 동안 먹여도 독작용은 없으며 부타디온에 의한 흰쥐의 위궤양 형성을 억제한다.Feeding polysaccharides in
또한 개에게 먹이면 위액의 분비량을 2.5배로 늘리며, 위액의 유리산도와 총산도를 20 내지 30% 높이고 위를 통하여 물질의 이동을 3~4배로 느리게 한다. Feeding dogs also increases the secretion of gastric juice by 2.5 times, increases the free acidity and total acidity of gastric juice by 20-30%, and slows the movement of material through the stomach by 3-4 times.
흰쥐의 떼낸 장에 대한 다당류의 진경작용은 1:10,000액에서도 나타난다. The hardening effect of polysaccharides on isolated intestines of rats is also shown in 1: 10,000 solution.
이와 같이 다당류는 진경작용과 항염증작용, 상피화 촉진작용이 있으므로 위궤양에 좋은 치료약이 된다. As such, polysaccharides have a hardening effect, anti-inflammatory action, and epithelialization promoting action, so it is a good medicine for gastric ulcer.
다당류의 작용상 특징은 높아진 산도를 낮추고 낮아진 산도를 높여 위액의 분비를 정상화시키며 특히 위액의 산도가 정상이거나 낮은 환자들에게 치료 효과가 좋다. The functional properties of polysaccharides lower the acidity and increase the acidity to normalize the secretion of gastric juice, especially in patients with normal or low acidity of gastric juice.
응용하는 곳은 전초에서 얻은 다당류 또는 생즙은 위액의 산도가 정상이거나 낮은 위십이지장궤양과 만성 위염에 쓴다. Applications include polysaccharides or fresh juices derived from outposts for gastric juices with normal or low gastric duodenal ulcers and chronic gastritis.
전초 달임약은 신석증에도 효과가 있다.Outpost decoction is also effective for nephropathy.
동의치료에서는 전초와 씨는 습열을 없애고 눈을 밝게 한다고 하여 눈병, 방광염, 장카타르, 피오줌, 설사, 적리에 염증약, 오줌내기약, 설사멎이약으로 쓴다. 또한 기침약으로 백날기침, 기관지염 등의 호흡기 질병에 사용을 하며, 민간에서는 전초를 위병과 기타 동맥경화, 당뇨병에 쓴다. 씨는 눈병, 신경계통 질병에 달여 마신다.In motion therapy, outposts and seeds are used to remove moist heat and brighten the eyes, so they are used as eye diseases, cystitis, jangkata, pissing, diarrhea, and inflammatory drugs, urinating drugs, and diarrhea. In addition, it is used as a cough medicine for respiratory diseases such as white cough and bronchitis. In civilian use, outposts are used for gastrointestinal diseases and other arteriosclerosis and diabetes. Mr. Moon drinks from eye diseases and nervous system diseases.
용규(Solanum nigrum)는 식물의 열매를 사용한다. Solanum nigrum uses the fruit of plants.
익은 열매에는 글리코알칼로이드, 사포닌과 안토시안 색소, β-카로텐 1,630mg%의 아스코르브산과 솔라소닌(0.2%), 솔라마르긴(0.25%)이 있다. Ripe fruits include glycoalkaloids, saponins and anthocyanin pigments, β-carotene 1,630 mg% ascorbic acid, solasonin (0.2%) and solamargin (0.25%).
작용으로 티푸스균, 포도알균, 녹농균, 적리균, 대장군, 진균에 대한 억제작용이 있으며 알칼로이드 성분은 폐나 기관지 조직중의 히스타민 분해를 촉진시키므로 기침멎이, 가래삭힘 작용을 나타내며, 혈압을 낮추는 등 주로 소화기, 순환계 질환 등을 다스리며 폐기능을 보호해준다It acts as an inhibitory effect against typhoid bacteria, staphylococcus aeruginosa, Pseudomonas aeruginosa, E. coli, coliform, and fungi.Alkaloids promote histamine breakdown in lung and bronchial tissues. Protects pulmonary function
응용하는 곳은 동의치료에서 강장약, 열내림약, 오줌내기약으로 피로를 회복하는데 쓴다.The application is to restore fatigue from motion therapy to tonic, fever and urinary medicine.
민간에서는 강장약, 오줌내기약으로 신석증, 물고임에 사용을 하며, 전초즙은 진정약, 진경약, 땀내기약으로 감기에 사용을 한다.In the private sector, it is used as a tonic medicine and urine medicine for nephropathy and bite water, and vinegar juice is used as a sedative medicine, jingyeong medicine, and sweat medicine for cold.
갈근(Pueraria thunbergiana Benth)은 다른 이름으로 칡덤불, 칡덩굴이라고 부르며 사용부위는 이른봄 또는 늦은 가을에 캐서 물에 씻은 다음 겉껍질을 벗겨서 사용한다. Pueraria thunbergiana Benth is another name called bush and vine, and the used part is used by digging in the early spring or late autumn and washing it with water.
성분으로는 뿌리에는 이소플라본화합물인 다이드제인(C15H10O4), 다이드진(C21H20O9),푸에라린(C21H20O9), 푸에라린크실로시드, 루테올린, 비오카닌 A(C16H12O5) 등과 농마,쿠마린이 있다. 또한 콜린, 아세틸콜린양물질, 카크코네인, 푸에라롤이 갈라졌다. Component in the roots at the isoflavone compound daidzein (C 15 H 10 O 4) , daidzin (C 21 H 20 O 9), the rarin (C 21 H 20 O 9) to Pu, Fu rarin xylose Seed, luteolin, biocanine A (C 16 H 12 O 5 ) and the like, there is a horse, coumarin. In addition, choline, acetylcholine-positive substances, cacaine, and puerarol cracked.
작용하는 곳은 온열중추를 자극한 집토끼에게 뿌리가루 15g/kg을 먹이면 뚜렷한 열내림작용이 있으면서도 다른 특별한 변화는 없다. Where it works, feeding the root powder 15g / kg to the heated rabbit stimulates the warming, but there is a distinct heat-lowering effect but no other special change.
뿌리의 이소플라본화합물은 진경작용이 있다. The isoflavone compound in roots has a hardening effect.
특히 이 작용은 다이드제인에서 강하다. 진경작용은 파파베린과 항아세틸콜린작용에 의한 것이다. In particular, this action is strong in dydzein. Cirrhosis is due to papaverine and antiacetylcholine action.
칡뿌리를 동의치료에서 진경약으로 머리아픔에 쓴 것은 이소플라본화합물에 의한 것으로 생각된다.Isoflavones are thought to have been used for the soreness of the roots as a medicinal agent in the synergistic treatment.
다이드제인을 편두통, 고혈압, 협심증 등 여러 가지 심장의 대상기능부전증에 사용예에 의하면, 심장피줄을 확장하여 70~80%의 환자에게서 치료효과가 있었다. According to an example of using dyedzein for various heart failures such as migraine, hypertension, and angina pectoris, cardiac extension of the heart was effective in 70-80% of patients.
그리하여 다이드제인은 고혈압, 편두통, 협심증에 쓰이고 있다. 뿌리에는 다이드제인의 진경작용에 길항하는 물질 즉 활평근장기를 강하게 수축시키는 물질이 있다. Thus, dyed jane is used for hypertension, migraine and angina. At the root, there is a substance that antagonizes dyspane's dystrophic action, that is, a substance that strongly contracts the smooth muscle organs.
응용하는 곳은 동의치료에서 뿌리와 꽃은 발한해열약, 진경약으로 열병에 쓰며 목안이 마르고 머리가 아플 때, 감기로 머리와 목이 아플 때, 편도염, 급성중이염에 쓴다.It is used in the treatment of motion in the roots and flowers are used for fever with antipyretic fever and sensitizing medicine. When the throat is dry and the head hurts, the cold and the head and neck hurts, tonsillitis and acute otitis media.
또한 소갈병, 열이나고 토하며 머리가 아프고 속이 답답한데, 목과 어깨가 뻗뻗한때 그리고 어혈을 풀고 상처를 아물게 하는데 사용을 하며, 잎은 고혈압으로 오는 머리아픔에 사용을 하며, 게움약, 오줌내기약으로도 사용을 하며, 뿌리는 고혈압, 폭발성귀울이때 쓴다.It is also used for small head sickness, fever and vomiting, pain in the head and stuffy stomach, when the neck and shoulders are stretched out, to loosen the blood and heal the wound, and the leaves are used for the head pain that comes with high blood pressure. Also used, the root is used for high blood pressure, explosive ear.
인동덩굴(Lonicera japonica Thunb)은 식물의 잎이 붙은 줄기를 베어 둥근 타래처럼 감아 햇볕에 말린 다음 줄기와 잎을 사용한다. Honeysuckle (Lonicera japonica Thunb) cuts the stems of the plant's leaves like a round skein, winds it up and dries it in the sun, then uses the stem and leaves.
성분으로는 잎과 줄기에 5~8%의 타닌질이 있고, 잎에는 로가닌, 약19%의 함 질소물질, 그리고 루테올린-7-람노글루코시드인 로니세린 (C27H30O15·2H2O) 이 있다. Ingredients include 5-8% tannins in the leaves and stems, loganine, about 19% nitrogenous content in the leaves, and roniserine, a luteolin-7-rhamnoglucoside (C 27 H 30 O 15 2H 2 O).
작용으로는 꽃 달인 물은 오줌내기 작용과 혈당량을 늘리는 작용이 있고 적리균, 티푸스균, 포도상구균, 폐렴쌍구균에 센 억균작용도 있다. 燒화성위궤양의 예방효과, 교감신경흥분, 평활근마비작용도 있다.Water decoction acts as a pissing action and increases blood sugar, and also has a fungal effect on erythrocytes, Typhoid bacteria, staphylococci, and pneumococci. 예방 There is also a protective effect of peptic ulcer, sympathetic nerve excitement, smooth muscle paralysis.
응용하는 곳은 동의치료에서 꽃과 잎, 줄기를 열내림약, 독풀이약, 오줌내기약, 정혈약으로 풍악초기에 열날 때, 종창과 종독, 여러 가지 창 독, 곪는 질병에 쓴다. It is used in motion therapy for flowers, leaves, and stems when it is opened early in Pung-kak with heat-lowering medicine, poisonous medicine, urinary medicine, and blood shaping medicine.
감초( Glycyrrhiza glabra L.)는 가을에 뿌리줄기와 뿌리를 캐어 줄기를 다듬고 물에 씻어서 햇볕에 말린 것을 사용한다. Licorice ( Glycyrrhiza glabra L.), in the fall, cut off the rhizome and roots, trim the stems, wash them in water and use them to dry in the sun.
성분으로는 뿌리와 줄기에는 글리시리진(글리시리진산의 칼륨염 또는 칼슘염)이 5~14%(많은 것은 23%), 글라브라산(글리시레틴) (C30H46O5)이 있다. Roots and stems contain 5-14% glycyrrhizine (potassium or calcium salt of glycyrrhizin acid) (23% more) and glabraic acid (glyciretin) (C 30 H 46 O 5 ).
글리시리진산(C42H62O16)은 트리테르페노이드사포닌으로 녹는점 205℃, 분해점 220℃, [α]D20 +58.5°이고 알코올과 뜨거운 물에 잘 풀리며 에테르에 풀리지 않는다. 뜨거운 물에 푼 것을 식히면 갖풀처럼 굳어진다. Glycilisic acid (C 42 H 62 O 16 ) is triterpenoids saponin, melting point 205 ℃,
물 분해하면 맛이 없는 글리시레틴산 (C30H46O4)과 2분자의 글루쿠론산 ( C6H10O7)이 생긴다. Decomposition of water results in tasteless glycyrrhetinic acid (C 30 H 46 O 4 ) and two molecules of glucuronic acid (C 6 H 10 O 7 ).
글리시레틴산은 β-아미린계 트리테르페노이드로 α,β체의 2가지가 있는데 쉽게 서로 변한다.Glycyretinic acid is a β-amirin-based triterpenoid, which has two kinds of α and β substances, which are easily changed.
α-글리시레틴산은 판 모양 결정(묽은알콜)이고 녹는점 283℃, [α]D20+140°(에탄올)이며 에탄올, 디옥산, 클로로포름에 풀린다. α-glyciretinic acid is a plate-like crystal (dilute alcohol), melting point 283 ° C., [α] D 20 + 140 ° (ethanol), soluble in ethanol, dioxane and chloroform.
β-글리시레틴산은 바늘결정(에탄올)이며 녹는점 296~300℃ [α]D20+86°(알코올)이고 에탄올, 피리딘, 초산에 풀리고 석유에테르에 잘 풀리지 않는다. β-Glycyretinic acid is needle crystal (ethanol), melting point 296 ~ 300 ℃ [α] D 20 + 86 ° (alcohol), soluble in ethanol, pyridine, acetic acid and insoluble in petroleum ether.
또한 플라보노 배당체인 리쿠이리틴 (C21H22O9), 네오리쿠이리틴, 람노리쿠이리틴(이것들의 비당부분은 모두 리쿠이리티게닌이다)과 이에 대응한 갈콘 배당체인 이소리쿠이리틴, 네오이소리쿠이리틴, 이소람노리쿠이리틴, 리쿠라시드(이것들의 비당 부분은 모두 이소리쿠이리티게닌이다)가 있다. In addition, flavono glycosides, liqueurin (C 21 H 22 O 9 ), neoriquirithins, and rhamnoricuritin (all of which are non-glycosides are liqueurinigen) and their corresponding galcon glycosides, isoricuitin , Neoisorikuuritin, isoram norikuuritin, and liqueuride (the non-sugar part of these are all Isorikuuritingenin).
감초뿌리에서 크로마토그라프로 27개를 넘는 플라보노이드 유사물질이 확인되었다. More than 27 flavonoid analogs were identified by chromatograph in licorice root.
굽은 감초 뿌리에서는 β-시토스테롤, 포르모노네틴, 리코리시딘, 리코리콘, 리코레올리그난이 확인되었다. Β-sitosterol, formmononetin, ricolycidine, lycoricone, and ricore-oligonane were identified in the curved licorice roots.
작용하는 곳은 감초 뿌리의 유효성분으로 알려져 있는 글리시리진의 물 분해에 의하여 생긴 글리시레틴산은 단맛이 없고 용혈작용이 있다. Glycyrrhinic acid produced by water decomposition of glycyrrhizin, known as an active ingredient of licorice root, has no sweetness and has a hemolytic action.
감초뿌리엑스, 글리시리진은 독성이 없고 포수클로랄, 스트리크닌, 요힘빈, 코카인, 모르핀, 코데인, 아트로핀, 루미날 등에 의한 중독을 풀어준다. Licorice root extract and glycyrrhizin are non-toxic and can relieve poisoning caused by po catchochloral, strycnin, yohimbine, cocaine, morphine, codeine, atropine and luminal.
세균독과 바이러스독, 예를 들면 파상풍 독소, 디프테리아 독소, 뱀 독을 풀어주며 아세틸콜린, 히스타민, 알레르기를 일으키는 물질과는 길항작용을 하며 아드레날린과 비슷한 강심작용도 있다. It releases bacterial and viral poisons such as tetanus toxin, diphtheria toxin and snake venom. It also antagonizes with acetylcholine, histamine and allergens, and has an adrenaline-like effect.
글리시리진의 독풀이 작용은 물 분해 산물인 글루쿠론산과 관계된다. The poisonous action of glycyrrhizin is related to glucuronic acid, a product of water degradation.
글루쿠론산은 동식물계에 널리 들어있는 성분으로 간에서 유독한 물질과 결합되어 글루쿠로니드를 형성하고 오줌으로 배설된다. Glucuronic acid is a component widely found in animal and plant systems and is combined with toxic substances in the liver to form glucuronide and excreted by urine.
그러므로 글루쿠론산은 약물중독, 알코올중독, 식중독, 황달, 간경변증, 만성간장에, 류머티즘, 관절아픔, 신경아픔 등에 쓰이고 있다. Therefore, glucuronic acid is used for drug addiction, alcoholism, food poisoning, jaundice, cirrhosis of the liver, chronic liver, rheumatism, joint pain, nerve pain.
글리시리진의 독풀이작용은 글루쿠론산에만 의한 것으로 생각되지 않으며 글리시리진이 부신피질호르몬과 비슷한 작용을 하는 것과도 관계된다. The detoxification of glycyrrhizin is not thought to be caused solely by glucuronic acid, but is also related to the action of glycyrazine similar to that of corticosteroids.
글리시리진은 부신피질 호르몬인 데스옥시코르티코스테론과 같은 효과가 있다. 글리시레틴산은 동물실험에서 나트륨과 클로르, 오줌의 배설량을 줄이고 칼륨의 배설량을 늘리고 Na/K의 비를 낮춘다. Glycirizine has the same effect as desoxycorticosterone, the corticosteroid. Glycyretinic acid reduces sodium, chlorine, and urine excretion, increases potassium excretion, and lowers the Na / K ratio in animal studies.
이와 같이 칼륨대사에는 부정적 영향을 주지만 나트륨대사에는 긍정적 영향을 준다. As such, it negatively affects potassium metabolism but positively affects sodium metabolism.
또한 물과 염류대사에 대한 부신피질 호르몬의 영향을 강화할 수 있도록 조건을 지어주는 부신피질의 아스코르브산 함량을 줄이는 작용을 한다. It also acts to reduce the ascorbic acid content of the adrenal cortex, which sets conditions to enhance the effects of corticosteroids on water and salt metabolism.
감초뿌리엑스 글리시리진은 항염증작용을 한다. 즉 동물에게 실험적으로 일으킨 포르말린 관절염의 치료에 긍정적 영향을 주고 혈청 트랜스아미나제의 활성을 억제하며 간에 있는 아데노신트리포스파타아제의 활성을 높인다. Licorice root extract glycyrrhizin is anti-inflammatory. In other words, it positively affects the treatment of experimentally induced formalin arthritis in animals, inhibits the activity of serum transaminase and increases the activity of adenosine triphosphatase in the liver.
글리시리진의 데스옥시코르티코스테론과 비슷한 항염작용은 분해 산물인 글리시레틴산에 의한 것으로 본다. The anti-inflammatory action of glycyrrhizin similar to desoxycorticosterone is believed to be due to the degradation product glycyrrhetinic acid.
감초뿌리엑기스는 동물실험에서 위장평활근에 대한 파파베린과 비슷한 향 근육성 진경작용이 있다. 이 작용은 플라보노이드 성분에 기인한다.Licorice root extract has a fascinating muscular dystrophy similar to papaverine on gastrointestinal smooth muscle in animal experiments. This action is due to the flavonoid component.
감초의 플라보노이드는 지금까지 쓰이지 않았던 것인데 진경작용, 항 염증작용이 알려지면서 개발되었다. 플라보노이드 성분인 리쿠라시드는 파파베린보다 3배나 센 진경작용이 있으면서도 항 염증, 항 궤양활성이 있다. 그리고 아세틸콜린, 히스타민에 대한 길항작용이 있다. Licorice flavonoids, which have not been used until now, was developed with known antifungal and anti-inflammatory effects. Licuraside, a flavonoid component, has three times as strong as papaverine and has anti-inflammatory and anti-ulcer activity. And antagonists of acetylcholine and histamine.
감초는 계면 활성이 세므로 다른 동약재와 달이거나 먹으면 동약성분을 물에 잘 풀리게 하여 흡수를 돕는다. 또한 동약재의 독성을 줄이고 맛을 바꾼다 요즘에는 에스트로겐 작용도 주목 되고 있다. 감초뿌리에는 포도알균, 대장균, 적리균에 대한 약간의 억제작용이 있다. 글리시리진산을 항암약인 티오폭스마미드와 함께 쓰면 항암 활성은 85~95%에 이른다고 한다. Licorice has a strong surface activity, so if you eat it with other copper medicines, it helps loosen the ingredients in water to help absorption. It also reduces the toxicity of the medicinal herbs and changes the taste. Licorice root has a slight inhibitory effect against Staphylococcus aureus, Escherichia coli, and Lycobacterium. When glycyrrhizin is used with anti-cancer drug thiopoxamide, anti-cancer activity reaches 85-95%.
응용하는 곳은 감초뿌리는 가래삭임작용, 완화작용, 항 염증작용과 진경작용, 항히스타민작용 등이 있다. 따라서 가래기침약으로 상기도 질병에 쓴다, 단맛이 있으므로 약품의 약고침약 및 독풀이약이나 부형약으로도 쓰인다. Its applications include sputum sputum, mitigating, anti-inflammatory and antifungal and antihistamine. Therefore, sputum acupuncture is used as an upper respiratory tract disease, because it has a sweet taste, it is also used as a drug medicinal acupuncture and poison medicine or excipient.
근래에는 위 십이지장궤양, 에디슨병, 기관지천식, 황달과 간염, 습진을 비롯한 피부병 등에 널리 쓰이고 있다. Recently, it is widely used for gastroduodenal ulcer, Edison's disease, bronchial asthma, jaundice and hepatitis, eczema and other skin diseases.
동의치료에서는 뿌리를 주로 다른 동약들의 작용을 완화 및 조화시킬 목적으로 많이 쓴다. 즉, 더운약과 같이 쓰면 열을 완화 시키며 찬 약과 같이 쓰면 찬 것을 완화시킨다. In motion therapy, the roots are used mainly for the purpose of alleviating and harmonizing the actions of other drugs. In other words, when used with hot medicine to relieve heat, and when used with cold medicine to relieve cold.
이처럼 완화약 또는 아픔멎이진경약, 가래약, 기침멎이약, 독풀이약으로 위경련, 위 아픔, 인후아픔, 위궤양, 십이지장궤양 등에 쓰며 독이 있는 동의처방에 들어간다. As a palliative or pain 멎 jinjak, sputum pill, cough 멎 yipo, poison pool medicine stomach cramps, stomach pain, sore throat, stomach ulcers, duodenal ulcers, etc. and enters the poisonous prescription.
치자(Gardenia jasminoides Ellis)의 성분으로는 열매에 이리도이드배당체인 게니핀 (C11H14O5)과 그 배당체인 게니포시드(C17H24O) 및 겐티오비오시드, 가르데노시드 그리고 노란 색소인 α-크로찐이 있다. 이 밖에 크산찔레틴, 프서랄렌, 페우쩨다놀메틸에스테르등 쿠마린성분이 있다. Gardenia (Gardenia jasminoides Ellis) consists of iridoid glycosides, genipine (C 11 H 14 O 5 ), its glycosides, geniposides (C 17 H 24 O) and genthiobiosides, gardenides and There is a yellow pigment, α-crochin. In addition, there are coumarin ingredients such as xantholeicin, praserene, and feudanol methyl ester.
작용하는 곳은 열매의 물 및 에탄올 추출액은 집토끼에게 먹일 때 열물분비를 뚜렷하게 항진시키지는 않으나 총수담관결찰때에는 빌리루빈이 피와 말초림파에로 나가는 것을 억제한다. 크로찐과 그의 나트륨염을 토끼귀정맥에 주사할 때 열분비물을 늘이고 총수담관을 잡아맨 토끼의 피로 나가는 것을 억제한다. 인돌계알카로이는 혈압내림작용을 한다. 열매를 흰생쥐에게 먹이면 약한 설사를 일으키는데 그 작용물질은 게니포시드이다.Where it works, the water and ethanol extract of the fruit does not significantly increase the secretion of heat when fed to the rabbit, but inhibits the bilirubin out into the blood and peripheral forest during total bile duct ligation. When crocin and its sodium salt are injected into the rabbit's vein, it increases heat secretion and suppresses the blood of the rabbit, which holds the total bile duct. Indole alkaloids lower blood pressure. Feeding the fruit to white mice causes mild diarrhea, the action of which is geniposide.
응용하는 곳은 동의치료에서 소염, 진정, 오줌내기, 열내림, 피멎이약으로, 염증, 출혈, 심근염, 토혈, 각혈, 황달에 사용을 한다. Applications include anti-inflammatory, sedative, urinary, fever-lowering, blood-repellent drugs in motion therapy, inflammation, bleeding, myocarditis, hemostasis, keratosis, and jaundice.
오미자( Schizandra chinensis Baillon = Schisandra chinensis )는 가을에 여문 열매를 따서 햇볕에 말린다음 그늘에서 말린 것을 사용한다. Schisandra chinensis (Schizandra chinensis Baillon = Schisandra chinensis ) picks ripe berries in the autumn and uses them to dry in the sun and then in the shade.
성분으로는 열매의 알코올엑스는 45~47%, 물엑스는 39~41%이며 많은 량의 유기산이 있다. Ingredients include 45% to 47% alcohol, 39% to 41% water, and organic acids.
씨까지 포함한 열매의 유기산 함량은 레몬산 10.9~12.8%, 사과산 7.6~10%, 포도주산 약 0.8%이다. 열매에는 또한 7.8%의 수지, 약 5%의 사포닌, 350~762mg%의 아스코르빈산이 있으며 씨에는 20~30%의 기름, 수지, 1.6~25의 정유, 리그닌화합물이 있다. The organic acid content of the fruit, including seeds, is 10.9-12.8% of lemon acid, 7.6-10% of malic acid, and 0.8% of grape acid. The fruit also contains 7.8% resin, about 5% saponin, 350-762 mg% ascorbic acid, and the seeds contain 20-30% oil, resin, 1.6-25 essential oils, and lignin compounds.
껍질은 레몬과 비슷한 냄새가 나며 풀색을 띤 누런색이며, 알데히드와 케톤이 약 20% 들어있다.The skin has a lemon-like odor and is a full yellowish color with about 20% aldehydes and ketones.
작용하는 곳은 열매의 우림약과 팅크는 중추신경에 대하여 오래 지속되는 흥분작용이 있으며 반사흥분성을 뚜렷이 높인다. It acts as a rainforest medicine and tincture of the fruit has a long-lasting excitatory effect on the central nervous system and remarkably enhances reflex excitability.
또한 근육신경의 흥분성을 높이고 말초신경계통의 기능을 좋게 하고 심장 피줄계통에 좋은 치료효과가 있다. In addition, it increases the excitability of the muscle nerve, improves the function of the peripheral nervous system and has a good therapeutic effect on the cardiovascular system.
슈잔드린은 척수의 반사흥분성을 높이며 심장 피줄계통과 호흡에 대한 긴장작용이 있고 탄수화물과 인대를 도우며, 조직 호흡을 빠르게 하고 효소들의 활성을 높여주며 동맥경화를 억제하며, 간염때 효소단위를 낮추는 작용도 있다.Suzandrarin increases the reflex excitability of the spinal cord, has a strain on the cardiac blood system and breathing, helps carbohydrates and ligaments, speeds up tissue breathing, increases the activity of enzymes, inhibits arteriosclerosis, and lowers enzyme units during hepatitis. There is also.
임상실험에 의하면, 전신쇠약, 신경쇠약, 전신분열증, 저혈압에 뚜렷한 치료효과가 있다. Clinical trials have a marked therapeutic effect on systemic weakness, nervous breakdown, systemic schizophrenia and hypotension.
오미자의 에칠알콜추출액은 동물실험에서 약물중독으로 높아진 혈청글루타님산초성트란스아미나제(SGPT)농도를 낮추며 간의 독풀이 기능을 강화하고 간글리코겐의 생성과 혈청단백질의 합성을 촉진한다. 임상적으로 만성비루스성간염이나 약물성간염에 어느정도 치료효과가 있고 특히 SGPT를 낮추는 작용이 뚜렷하다.Schizandra chinensis alcohol extract lowers serum glutanic acid acetate transaminasase (SGPT) concentration, which is increased due to drug addiction in animal experiments, strengthens liver detoxification function, and promotes liver glycogen production and serum protein synthesis. Clinically, it has some therapeutic effects on chronic viral hepatitis and drug hepatitis, and the effect of lowering SGPT is obvious.
응용하는 곳은 전신쇠약, 정신육체적피로, 신경쇠약, 저혈압, 심장기능저하, 영양실조성궤양에 사용됨과 아울러 시력을 높이기 위해 쓴다. Applications include systemic weakness, mental and physical fatigue, nervous breakdowns, hypotension, heart failure, malnutrition ulcers, and to improve vision.
또한 열매와 씨는 간질병에 쓰면 실험실 검사지표가 뚜렷하게 좋아진다는 임상검토 자료들이 알려지고 있다.In addition, clinical reviews have shown that fruit and seeds can significantly improve laboratory test indicators when used in epilepsy.
동의치료에서는 폐를 보하고 콩팥을 돕는 목적에 기침멎이약, 수렴약, 자양강장약으로 기침, 입안이 마르며 설사가 멎지 않고 땀이 나고 가래가 많은 때 사용을 하며, 민간에서는 오미자 가루를 효소단위가 높은 간기능 장애 시, 가래약 오줌내기약, 즙은 유정때 강정약으로 사용한다.In motion therapy, cough, astringent, astringent, and nourishing tonic are used to protect the lungs and to help the kidneys. Cough, dry mouth, diarrhea and sweating and sputum are often used. In case of high liver dysfunction, sputum pee urine and juice are used as a potent tablet in oil wells.
위와 같은 성분과 효능을 가진 천연 생약제를 본 발명에서 제시하는 생약제 조성물을 얻기 위한 생약제의 유효성분 엑기스 각 추출 방법은 하기와 같다.
삼백초는; Each extraction method of the active ingredient extract of the herbal medicine to obtain the herbal composition with the above ingredients and efficacy as shown in the present invention is as follows.
Three hundred seconds;
삭제delete
삼백초 건조분말 10kg에 C1 -4 의 저급알코올(50% 에탄올) 10배수를 가하고 75℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다.10 kg of low alcohol (50% ethanol) of C 1-4 was added to 10 kg of the dry powder of 300 seconds, and extracted with gentle stirring for 5 hours while maintaining 75 ° C or more.
수득한 생성물은 원심분리한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 6kg~7kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 6㎏~7㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다. The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 6 kg-7 kg was obtained as an extract. The extract is aged and fermented (when fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ° C. to 40 ° C.) to obtain 6 kg to 7 kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
삭제delete
이질풀은;Heterogeneous grass;
이질풀 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다. 10 kg of dry grass powder is added, and 10 times of purified water is added and extracted with gentle stirring for 5 hours while maintaining at 95 ° C or more.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 6kg~7kg을 수득하였다. The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 6 kg-7 kg was obtained as an extract.
이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 6㎏~7㎏을 수득한다.또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다. The extract is aged and fermented (when fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ° C. to 40 ° C.) to obtain 6 kg to 7 kg. The extract also contains fungi commonly used in food fermentation processes. Microbial fermentation can be used.
흑두는;Dark bean;
흑두 건조분말 10kg에 정제수 10배수를 가하고 상온에서 12시간을 추출한다. 10 kg of purified water is added to 10 kg of black bean dry powder, and extracted at room temperature for 12 hours.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약40%의 고형분 함량이 되도록 농축한 다음 엑기스로서 7kg~8kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 7㎏~8㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 40%, and 7 kg-8 kg was obtained as an extract. This extract is aged and fermented (when fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ~ 40 ℃) to obtain 7kg ~ 8kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
차전초는;Charcoal;
차전초 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다. 10 kg of dried water was added to 10 kg of dried powder of chajeoncho, and extracted with gentle stirring for 5 hours while maintaining 95 ° C or more.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. 감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure. The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 4kg ~ 5kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
용규는;Yonggyu is;
용규건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다. To 10 kg of dry silica powder, add 10 times of purified water and extract with gentle stirring for 5 hours while maintaining 95 ℃ or more.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. 감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약55%의 고형분 함량이 되도록 농축한 다음 엑기스로서 5kg~6kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 5㎏~6㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
갈근은; The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure. The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 55%, and then 5 kg to 6 kg was obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 5kg ~ 6kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
Brown root;
삭제delete
갈근 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다. 10 kg of dried dry powder is added, and 10 times of purified water is extracted.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 4kg ~ 5kg. In addition, the extract may be microbial fermentation using fungi commonly used in food fermentation process.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
인동덩굴은;Honeysuckle;
삭제delete
인동덩굴 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다. 10 kg of dried honeysuckle powder is added, and 10 times of purified water is extracted.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 6kg~7kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 6㎏~7㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 6 kg-7 kg was obtained as an extract. The extract is aged and fermented (when fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ° C. to 40 ° C.) to obtain 6 kg to 7 kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
감초는;Licorice is;
감초 건조분말 10kg에 C1 -4 의 저급알코올(40%에탄올) 10배수를 가하고 70℃이상을 유지하면서 5시간을 서서히 교반하면서 1차 추출한 후 생성물은 1차 보관하고, 다시 40%에탄올 7배수를 가하고 5시간에서 2차 추출한다. 10 kg of low alcohol (40% ethanol) of C 1-4 was added to 10 kg of licorice dry powder, and primary extraction was carried out while stirring slowly for 5 hours while maintaining at 70 ° C. or higher. Add and extract secondary at 5 hours.
1차와 2차에서 수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다. The products obtained in the primary and secondary are centrifuged, the solid residue is discarded, the extract is left for 1 day, the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 5kg~6kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 5㎏~6㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 5 kg to 6 kg was obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 5kg ~ 6kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
치자는;Gardenia;
치자 건조분말 10kg에 C1 -4 의 저급알코올(40%에탄올) 10배수를 가하고 25℃에서 12시간을 서서히 교반하면서 추출한다. 10 kg of lower alcohol (40% ethanol) of C 1-4 was added to 10 kg of Gardenia dried powder, and extracted with 25 hours of stirring at 25 ° C.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 6kg~7kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 6㎏~7㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 6 kg-7 kg was obtained as an extract. The extract is aged and fermented (when fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ° C. to 40 ° C.) to obtain 6 kg to 7 kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
오미자는;Schisandra;
삭제delete
오미자 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다. 10 kg of dried powder of Schizandra chinensis shall be added with 10 times of purified water and extracted with gentle stirring for 5 hours while maintaining 95 ℃ or more.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축하였다. 감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 5kg~6kg을 수득한다. The obtained product was centrifuged, the solid residue was discarded, the extract was left for 1 day, and the supernatant was filtered and concentrated under reduced pressure. The concentration under reduced pressure is concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component is concentrated to a solid content of about 60%, and then 5 kg to 6 kg are obtained as an extract.
이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 5㎏~6㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
한편 본 발명에서는 위 생약제 두충, 산약, 토목령, 유근피, 현호색, 맥운동과 같은 생약제 중 선택된 1종 이상을 추가할 수 있고, 위 생약제의 유효성분 추출방법은 다음과 같다.
두충은;
두충 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
토복령은;
토복령 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
산약은;
산약 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
유근피는;
유근피 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
현호색은;
현호색 건조분말 10kg에 C1 -4 의 저급알코올(40%에탄올) 10배수를 가하고 70℃이상을 유지하면서 5시간을 서서히 교반하면서 1차 추출한 후 생성물은 1차 보관하고, 다시 40%에탄올 7배수를 가하고 5시간에서 2차 추출한다.
1차와 2차에서 수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 4kg~5kg을 수득하였다. 이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 4㎏~5㎏을 수득한다.또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
맥문동은;
맥문동 건조분말 10kg에 정제수 10배수를 가하고 95℃이상을 유지하면서 5시간을 서서히 교반하면서 추출한다.
수득한 생성물은 원심분리 한 후 고체 잔류물은 버리고 추출액을 1일간 방치한 후 상등액을 여과하여 감압 농축한다.
감압 농축시 온도는 55℃에서 감압(70~76mmHg) 농축하며, 수득한 고형성분을 약60%의 고형분 함량이 되도록 농축한 다음 엑기스로서 5kg~6kg을 수득한다.
이 엑기스를 숙성발효(숙성발효 시 온도는 30℃~40℃를 유지하면서 40일간 숙성발효화 함)하여 5㎏~6㎏을 수득한다. 또한 상기 엑기스는 식품 발효공정에서 통상적으로 사용되는 진균을 이용한 미생물 발효할 수 있다.
상기에서 각 천연 생약제에서 엑기스를 추출할 때 각 천연 생약제의 건조분말과 혼합되는 용매는 위 설명과 같이 정제수 또는 C1 -4 의 저급알코올로 할 수 있으나 위 용매는 정제수와 C1 -4 의 저급알코올의 혼합용매로 할 수 있다.
다음으로 상기의 천연 생약제의 엑기스를 수득하기 위해서는 각 성분을 동시에 또는 별개로 수성용매(예 : 물 단독 또는 친수성유기용매, 예컨데, 메탄올, 에탄올등과의 혼합액, ethyl acetete)의 과잉량 즉 5~20배의 량과 혼합하고, 이혼합물을 40℃~95℃에서 충분한 시간 약 3~10시간 추출하여 고체를 제거하고, 추출액을 감압하에 농축한 다음 미생물을 이용한 미생물발효와 숙성발효를 할 수도 있다.
또한 상기에서 삼백초, 이질풀, 흑두, 차전초, 용규, 갈근, 인동덩굴, 감초, 치자, 오미자 엑기스를 각 1중량씩 혼합하여 동결건조시켜서 주 생약 조성물을 얻거나 또는 상기 주 생약조성물에 두충, 산약 토복령, 유근피, 현호색 맥운동 중 선택된 1종 이상의 엑기스를 동결건조한 동결건조물을 추가로 첨가할 수 있다.
이하에서 기재된 것은 본 발명을 통해 얻어진 생약 조성물의 실험 예로서 본 발명의 효능을 측정하였다.This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 5kg ~ 6kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
On the other hand, in the present invention, one or more selected from the herbal medicines such as stomach medicinal herb, pesticide, civil engineering, Yugeunpi, Hyunho-color, pulse movement can be added, and the active ingredient extraction method of the herbal medicine is as follows.
Toothworm;
10 kg of purified water was added to 10 kg of Tofu dry powder, and extracted with gentle stirring for 5 hours while maintaining 95 ° C or more.
The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 4kg ~ 5kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
Tobok-ryeong;
10 kg of purified water was added to 10 kg of Tobokyeong dry powder, and extracted with gentle stirring for 5 hours while maintaining 95 ° C or more.
The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 4kg ~ 5kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
The potion is;
To 10 kg of powdered dry powder, add 10 times of purified water and extract with gentle stirring for 5 hours while maintaining 95 ℃ or more.
The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 4kg ~ 5kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
Root skin;
10 kg of purified water was added to 10 kg of dried root powder, and extracted with gentle stirring for 5 hours while maintaining 95 ° C or more.
The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 4kg ~ 5kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
Cormorant color;
10 kg of low alcohol (40% ethanol) of C 1-4 was added to 10 kg of the coarse orange dry powder, and primary extraction was carried out while stirring slowly for 5 hours while maintaining at 70 ° C. or higher. Add and extract secondary at 5 hours.
The products obtained in the primary and secondary are centrifuged, the solid residue is discarded, the extract is left for 1 day, the supernatant is filtered and concentrated under reduced pressure.
The concentration under reduced pressure was concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component was concentrated to a solid content of about 60% and 4 kg to 5 kg were obtained as an extract. The extract is aged for fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ° C. to 40 ° C.) to obtain 4 kg to 5 kg. Microbial fermentation can be used.
Pulmonary sinus;
Add 10 times purified water to 10 kg of dried powder powder and extract with gentle stirring for 5 hours while maintaining 95 ℃ or more.
The obtained product is centrifuged, the solid residue is discarded, the extract is left for 1 day, and the supernatant is filtered and concentrated under reduced pressure.
The concentration under reduced pressure is concentrated at 55 ° C. under reduced pressure (70-76 mmHg), and the obtained solid component is concentrated to a solid content of about 60%, and then 5 kg to 6 kg are obtained as an extract.
This extract is aged by fermentation (fermentation fermentation is carried out for 40 days while maintaining the temperature of 30 ℃ ~ 40 ℃) to obtain 5kg ~ 6kg. In addition, the extract may be fermented microorganisms using fungi commonly used in food fermentation process.
When the extract is extracted from each natural herbal medicine, the solvent mixed with the dry powder of each natural herbal medicine may be purified water or lower alcohol of C 1-4 as described above, but the solvent may be purified water and lower C 1-4. It can be used as a mixed solvent of alcohol.
Next, in order to obtain the extract of the natural herbal medicine, each component may be used simultaneously or separately in an excess amount of an aqueous solvent (for example, water alone or a hydrophilic organic solvent, for example, a mixture of methanol and ethanol, ethyl acetete), that is, 5 to 20 After mixing with the amount of the pear, and distilled mixture is extracted for about 3 to 10 hours at 40 ℃ ~ 95 ℃ for a sufficient time to remove the solids, the extract is concentrated under reduced pressure, and then microbial fermentation and aging fermentation using microorganisms.
In addition, the above three hundred seconds, yirum grass, black bean, chajeoncho, yonggyu, brown root, honeysuckle, licorice, gardenia, Schisandra chinensis extract by mixing each one by weight to obtain the main herbal composition, or to the main herbal composition to worms, powdered soil Freeze-dried lyophilized one or more extracts selected from Fukryeong, Yu-Geun Skin and Hyun-ho-Sang pulse exercise may be added.
What is described below measured the efficacy of the present invention as an experimental example of the herbal composition obtained through the present invention.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
실험 예 1 Experimental Example 1
동물임상실험에 의한 혈액중의 니코틴 분해능 측정Determination of Nicotine Degradation in Blood by Animal Clinical Trials
1) 시험동물 1) Test Animal
Wister strain 수컷 랫트(6주령)는 (주)샘타코(경기도 오산시)로부터 구입. Wister strain male rats (6 weeks old) are purchased from Samtaco (Osan-si, Gyeonggi-do).
2) 시험환경 2) Test environment
동물을 실온 22±1℃, 습도 55±5%, 환기회수 12회/시간, 조명시간 12시간/일(아침 8시점등, 밤 8시 소등) 로 설정된 동물실의 철망 사육실에 5마리씩 수용하였다. 사료는 고체사료(Sam#31(Autoclavable)를 물과 함께 섭취하게 하였다. Animals were housed in 5 wire cages in an animal room set at room temperature 22 ± 1 ° C., humidity 55 ± 5%, ventilation time 12 times / hour, lighting time 12 hours / day (light at 8 am, light at 8 pm). . Forage was fed solid water (Sam # 31 (Autoclavable)) with water.
3) 투여방법 3) Administration method
시험환경에 2주간 적응시키고 8주령에서 동물을 사용하였다. Adapted to the test environment for 2 weeks and animals were used at 8 weeks of age.
시험물질은 본 조성물 0.4g과 고체사료 3.6g에 섞어서 Total 4g을 물과 함께 자유로 먹이로서 체내에 경구 투여하였다. The test substance was mixed with 0.4 g of the composition and 3.6 g of solid feed, and total 4 g was orally administered to the body as free food with water.
4)투여시간 4) Dosing time
투여는 오후 2시에 실시하고, 기간은 7일간으로 하였다. Administration was performed at 2 pm and the period was 7 days.
투여 종료시 및 시험 종료시에 니코틴 분해능 측정을 위한 시료로 심장으로부터 1ml 채혈하였다. At the end of dosing and at the end of the test, 1 ml of blood was drawn from the heart as a sample for nicotine resolution measurement.
5) 관찰방법 5) Observation Method
투여일은 투여직후와 저녁에, 그 다음날부터는 아침과 저녁에 관찰하였다. 관찰은 동물을 사육자 바깥으로부터 주의 깊게 실시하였다 Dosing days were observed immediately after administration and in the evening, and the morning and evening thereafter. Observation was done carefully from outside the breeder
6) 혈액중 니코틴 분해능의 측정시험결과6) Test result of nicotine resolution in blood
혈액을 묽은 암모니아수로 pH 9로 조절하였다. 이어서 EXTRELUT COLUMN.(Merck사 제품)에 15분간 유지시키고 15ml의 에틸 아세테이트로 용출 한 다음, 용출아세테이트를 감압하에 증류 제거하고, 생성된 잔사에 100㎕의 에틸 아세테이트를 가하여 용해시키고 분석시료로 하였다 Blood was adjusted to pH 9 with dilute ammonia water. Subsequently, the resultant was kept in EXTRELUT COLUMN. (Manufactured by Merck Co., Ltd.) for 15 minutes, eluted with 15 ml of ethyl acetate, the eluted acetate was distilled off under reduced pressure, and 100 µl of ethyl acetate was added to the resulting residue to dissolve.
분석은 가스크로마토그래피(미국 HP사 5890 SERIESП, FID부착)사용. For analysis, use gas chromatography (HP 5890 SERIESП with FID).
COLUMN 은 2% Tharmon 1000+1% KOH Chromosorb WAM(8/100Mesh)를 충전한 길이 2m, 직경 3mm의 유리 칼럼을 사용하였다.COLUMN used a glass column 2 m long and 3 mm in diameter filled with 2
COLUMN온도는 100℃, 캐리어 기체는 N2를 사용하였고 유속은 60ml/분으로 하 였다. COLUMN temperature was 100 ℃, N 2 was used as the carrier gas and the flow rate was 60ml / min.
표1. 본 조성물 7일 투여후의 결과 Table 1. Results after 7 days administration of the composition
참고사항 : G1 : 본 조성물 전처치후 Nicotine 투여. Note: G1: Nicotine administration after pretreatment of the composition.
G2 : 본 조성물 전처치후 Nicotine 투여후 해독제 투여. G2: Anti-drug administration after Nicotine administration after pretreatment of this composition.
G3 : 대조군 Nicotine투여. G3: control Nicotine.
G4 : 대조군 Nicotine투여후 본 발명품 투여. G4: Administration of the invention after administration of control Nicotine.
시험 개체수는 각 군별로 열마리씩 시험하였다 Ten test subjects were tested in each group.
Nicotine 농도 40mg/kg/몸무게 대비(투여량 ml) Nicotine concentration 40mg / kg / weight ratio (dose ml)
실험 예 2 Experimental Example 2
동물임상실험에 의한 뇨중의 니코틴 분해능 측정Determination of Nicotine Degradation in Urine by Animal Clinical Experiment
1) 시험동물 1) Test Animal
Wister strain 수컷 랫트(6주령)는 (주)샘타코(경기도 오산시)로부터 구입. Wister strain male rats (6 weeks old) are purchased from Samtaco (Osan-si, Gyeonggi-do).
2) 시험환경 2) Test environment
동물을 실온 22±1℃, 습도 55±5%, 환기회수 12회/시간, 조명시간 12시간/일(아침 8시 점등, 밤 8시 소등) 로 설정된 동물실의 철망 사육실에 5마리씩 수용하였다. 사료는 고체사료(Sam#31(Autoclavable)를 물과 함께 섭취하게 하였다. Five animals were housed in a wire cage in an animal room set at room temperature 22 ± 1 ° C., humidity 55 ± 5%, ventilation number 12 times / hour, lighting time 12 hours / day (light at 8 am, light at 8 pm). . Forage was fed solid water (Sam # 31 (Autoclavable)) with water.
3) 투여방법 3) Administration method
시험환경에 2주간 적응시키고 8주령에서 동물을 사용하였다. Adapted to the test environment for 2 weeks and animals were used at 8 weeks of age.
시험물질은 본 조성물 0.4g과 고체사료 3.6g에 섞어서 Total 4g을 물과 함께 자유로 먹이로서 체내에 경구 투여하였다. The test substance was mixed with 0.4 g of the composition and 3.6 g of solid feed, and total 4 g was orally administered to the body as free food with water.
4)투여시간 4) Dosing time
투여는 오후 2시에 실시하고, 기간은 7일간으로 하였다. Administration was performed at 2 pm and the period was 7 days.
투여 종료시 및 시험 종료시에 니코틴 분해능 측정을 위한 시료로 방광으로부터 1ml 채혈하였다. At the end of dosing and at the end of the test, 1 ml of blood was collected from the bladder as a sample for measuring nicotine resolution.
5) 관찰방법 5) Observation Method
투여일은 투여직후와 저녁에, 그 다음날부터는 아침과 저녁에 관찰하였다. 관찰은 동물을 사육자 바깥으로부터 주의 깊게 실시하였다 Dosing days were observed immediately after administration and in the evening, and the morning and evening thereafter. Observation was done carefully from outside the breeder
6) 뇨중 니코틴 분해능의 측정시험결과6) Test result of nicotine resolution in urine
뇨를 묽은 암모니아수로 pH9로 조절하였다. 이어서 EXTRELUT COLUMN. (Merck 사 제품)에 15분간 유지시키고 15ml의 에틸 아세테이트로 용출 한 다음, 용출아세테이트를 감압하에 증류 제거하고, 생성된 잔사에 100㎕의 에틸 아세테이트를 가하여 용해시키고 분석시료로 하였다.Urine was adjusted to pH 9 with dilute ammonia water. Then EXTRELUT COLUMN. (Merck Co., Ltd.) was maintained for 15 minutes, eluted with 15 ml of ethyl acetate, the eluted acetate was distilled off under reduced pressure, and 100 µl of ethyl acetate was added to the resulting residue to dissolve and used as an assay sample.
분석은 가스크로마토그래피(미국 HP사 5890 SERIESП, FID부착)사용. For analysis, use gas chromatography (HP 5890 SERIESП with FID).
COLUMN은 2% Tharmon 1000+1% KOH Chromosorb WAM(8/100Mesh)를 충전한 길이 2m, 직경 3mm의 유리 칼럼을 사용하였다.COLUMN was filled with 2
COLUMN온도는 100℃, 캐리어 기체는 N2를 사용하였고 유속은 60ml/분으로 하였다.The COLUMN temperature was 100 ° C, the carrier gas was N 2 , and the flow rate was 60 ml / min.
표2. 본 조성물 7일 투여후의 결과 Table 2. Results after 7 days administration of the composition
참고사항 : G1 : 본 조성물 전처치후 Nicotine 투여. Note: G1: Nicotine administration after pretreatment of the composition.
G2 : 본 조성물 전처치후 Nicotine 투여후 해독제 투여. G2: Anti-drug administration after Nicotine administration after pretreatment of this composition.
G3 : 대조군 Nicotine투여. G3: control Nicotine.
G4 : 대조군 Nicotine투여후 본 발명품투여. G4: Administration of the invention after administration of control Nicotine.
시험 개체수는 각 군별로 열마리씩 시험하였다Ten test subjects were tested in each group.
Nicotine 농도 40mg/kg/몸무게 대비(투여량 ml) Nicotine concentration 40mg / kg / weight ratio (dose ml)
실험 예 3 Experimental Example 3
동물임상실험에 의한 혈액중 일산화탄소 농도 측정Determination of Carbon Monoxide Concentration in Blood by Animal Clinical Experiment
1) 시험동물 1) Test Animal
Wister strain 수컷 랫트(6주령)는 (주)샘타코(경기도 오산시)로부터 구입. Wister strain male rats (6 weeks old) are purchased from Samtaco (Osan-si, Gyeonggi-do).
2) 시험환경 2) Test environment
동물을 실온 22±1℃, 습도 55±5%, 환기회수 12회/시간, 조명시간 12시간/일(아침 8시점등, 밤 8시 소등) 로 설정된 동물실의 철망 사육실에 5마리씩 수용하였다. 사료는 고체사료(Sam#31(Autoclavable)를 물과 함께 섭취하게 하였다. Animals were housed in 5 wire cages in an animal room set at room temperature 22 ± 1 ° C., humidity 55 ± 5%, ventilation time 12 times / hour, lighting time 12 hours / day (light at 8 am, light at 8 pm). . Forage was fed solid water (Sam # 31 (Autoclavable)) with water.
3) 투여방법 3) Administration method
시험환경에 2주간 적응시키고 8주령에서 동물을 사용하였다. Adapted to the test environment for 2 weeks and animals were used at 8 weeks of age.
시험물질은 본 조성물 0.4g과 고체사료 3.6g에 섞어서 Total 4g을 물과 함께 자유로 먹이로서 체내에 경구 투여하였다. The test substance was mixed with 0.4 g of the composition and 3.6 g of solid feed, and total 4 g was orally administered to the body as free food with water.
4) C0 폭로 방법 4) C0 expose method
투여 종료 다음날, 폭로용 챔버(일본국 Sugiyamage사 제품)내에 각 동물을 수용하고, O2 21%, CO 100ppm의 혼합기체를 펌프로 도입하여 5분간 흡입시켰다. 챕버내의 농도는 일산화탄소 측정기 (COM-4, 일본국 Komei Rikagaku Kogyo사 제품)로서 검사하였다. The day after the end of the administration, each animal was housed in an exposure chamber (manufactured by Sugiyamage, Japan), and a mixed gas of 21% O 2 and 100 ppm CO was introduced into the pump and aspirated for 5 minutes. The concentration in the chapter was examined with a carbon monoxide meter (COM-4, manufactured by Komei Rikagaku Kogyo, Japan).
5) 혈액중 CO - Hb 농도의 측정 5) Measurement of CO-Hb Concentration in Blood
폭로종료 후 바로 심장으로부터 채혈하여 혈액 0.5ml을 5ml 용량의 reaction vial에 넣고 옥틸알콜 한방울과 포타슘 페리시아네이트 포화 수용액 0.25ml를 가하였다. 반응액을 마개로 막고 5분간 진탕한 후 기상(氣相)을 분석 시료로 사용하였다. Immediately after the end of the exposure, blood was drawn from the heart, 0.5 ml of blood was added to a 5 ml volume of reaction vial, and one drop of octyl alcohol and 0.25 ml of saturated aqueous potassium ferricate solution were added. After the reaction solution was capped and shaken for 5 minutes, gas phase was used as analytical sample.
분석은 가스크로마토그래피(미국 HP사 5890 SERIESП, TCD부착)사용. For analysis, use gas chromatography (HP 5890 SERIESП, TCD).
COLUMN은 분자체 5A(3/60Mesh)를 충전한 길이 2m, 직경 3mm의 유리 칼럼을 사용하였다. COLUMN used a glass column 2m in length and 3mm in diameter filled with molecular sieve 5A (3 / 60Mesh).
COLUMN온도는 60℃, 캐리어 기체는 H2를 사용하였고 유속은 50ml/분으로 하였다. The COLUMN temperature was 60 ° C., the carrier gas was H 2 , and the flow rate was 50 ml / min.
6) 결과 6) Results
시험 후의 혈액중 CO농도를 측정한 결과는 표3에 나와 있다. The results of measuring the CO concentration in the blood after the test are shown in Table 3.
표3. 본 조성물을 10일 투여후의 결과 Table 3. Results after 10 days administration of this composition
실험 예 4 Experimental Example 4
항산화효과Antioxidative effect
자유 라디칼들이 동맥경화(Palinski, W., Rosenfeld, M. E., Yla, H. S., Gurtner, G. C., Socher, S. S., Butler, S. W., Carew, T. E., Steinberg, D., and Witztum, J. L. (1989) Proc . Natl . Acad . Sci ., 86, 1372-1376), 혈관수축에 의한 국소빈혈(Hammond, B., Kontos, H. A., and Hess, M. L. (1985) Can . J. Physiol . Pharmacol., 63, 173-187), 염증(Cheeseman, K. H., and Forni, L. G. (1988) Biochem . Pharmacol., 37, 4225-4233), 발암(Weitzman, S. A., Weitberg, A. B., Clark, E. P., and Stossel, T. P. (1985) Science, 227, 1231-1233), 류마티스성 관절염(Fantone, J. C., and Ward, P. A. (1985) Human Pathol ., 16, 973-978)과 같은 넓은 범위의 병을 매개한다는 다양한 증거들이 알려져 왔다. 그러므 로, 자유 라디칼 포착제(scavenger)는 자유 라디칼 수준을 감소시킴으로써 효과적인 치료제로써 기대 되어 지고 있으며, 사람들은 안전하고 효과적인 항산화제의 개발에 초점을 맞추어 왔다.Free radicals are atherosclerosis (Palinski, W., Rosenfeld, ME, Yla, HS, Gurtner, GC, Socher, SS, Butler, SW, Carew, TE, Steinberg, D., and Witztum, JL (1989) Proc . Natl . Acad. Sci., 86, 1372-1376), ischemia by vasoconstriction (Hammond, B., Kontos, HA , and Hess, ML (1985) Can. J. Physiol. Pharmacol., 63, 173-187 ), Inflammation (Cheeseman, KH, and Forni, LG (1988) Biochem . Pharmacol ., 37, 4225-4233), carcinogenesis (Weitzman, SA, Weitberg, AB, Clark, EP, and Stossel, TP (1985) Science , 227, 1231-1233), rheumatoid arthritis (Fantone, JC, and Ward, PA (1985) Human Pathol . , 16, 973-978). Various evidences have been known to mediate a wide range of diseases. Therefore, free radical scavenger is expected to be an effective treatment by reducing free radical levels, and people have focused on developing safe and effective antioxidants.
본 실험에서는 자유 라디칼인 DPPH(1,1-diphenyl-2-picrylhydrazyl)와 Flow-Injection Chemiluminescence (FI-CL)에 의한 항산화 효과 측정 방법 (Analytical Biochemistry 264, 291-293) SOD(superoxide dismutase) 기능성 제제에 대하여 실험하였다.In this experiment, a method for measuring antioxidant effects by free radicals DPPH (1,1-diphenyl-2-picrylhydrazyl) and Flow-Injection Chemiluminescence (FI-CL) (Analytical Biochemistry 264, 291-293) SOD (superoxide dismutase) functional agent Was tested against.
1) DPPH (1,1-diphenyl-2-picryl-hydrazyl)에 의한 항산화 효과 측정 방법 1) Method of measuring antioxidant effect by DPPH (1,1-diphenyl-2-picryl-hydrazyl)
안정한 free radical인 DPPH를 ethanol에 녹여 0.5 mM solution을 만들고, DPPH solution 1 ml에 100 mM Tris-HCl buffer (pH 7.4) 1 ml를 넣고, 0.5% test sample을 0.1 ml 첨가하여 37℃, 암실에서 15분간 반응시킨 후 517 nm에서 흡광도를 측정했다. 흡광도는 HP UV/VIS spectrophotometer를 사용하여 측정하였다. 각 test sample의 항산화 효과는 DPPH만 넣고 시료를 넣지 않은 control의 UV 흡광도와 DPPH에 0.5%의 sample을 넣은 시험관의 흡광도의 감소를 비교하였다. 본 조성물의 radical scavenging activity를 % inhibition으로 나타내었다. Dissolve the stable free radical DPPH in ethanol to make 0.5 mM solution, add 1 ml of 100 mM Tris-HCl buffer (pH 7.4) to 1 ml of DPPH solution, and add 0.1 ml of 0.5% test sample to 15 ℃ in the dark. After the reaction, the absorbance was measured at 517 nm. Absorbance was measured using an HP UV / VIS spectrophotometer. The antioxidant effect of each test sample was compared with the UV absorbance of the control without DPPH but no sample and the absorbance of the test tube with 0.5% sample in DPPH. The radical scavenging activity of the composition was expressed as% inhibition.
% Inhibition = [A-B]/[A] x 100 % Inhibition = [A-B] / [A] x 100
A : DPPH만의 흡광도 A: absorbance only DPPH
B : DPPH + sample(scavenger)을 혼합한 sample 흡광도 B: Sample absorbance mixed with DPPH + sample (scavenger)
2) Flow-Injection Chemiluminescence (FI-CL)에 의한 항산화 효과 측정 방법 (Analytical Biochemistry 264, 291-293) 2) Method of measuring antioxidant effect by Flow-Injection Chemiluminescence (FI-CL) (Analytical Biochemistry 264, 291-293)
화학발광 detector를 이용하여 과산화수소에 의해 발생되는 ROS(reactive oxygen species)의 제거를 통해 항산화 효과를 알아볼 수 있는 방법이다. CL intensity는 filter equipped photon counting 형태인 spectrophotometer (CLA-1100, Tohoku Electronic Industry)에 pump (Gilson Model 306) 와 injector (Rheodyne Model 7125)를 연결하여 측정하였다. 화학발광은 cytochrome c 와 H2O2가 반응하여 oxygen-derived free radical이 생성되고, 이 생성물이 luminol과 반응하여 luminol의 산화가 일어나면서 화학발광이 일어난다. 이 때 radical scavenger의 역할을 하는 항산화 물질에 의하여 활성산소의 reduction이 일어나 CL intensity가 감소한다. Mobile phase는 50% methanol로 만들어진 50 mM phosphate buffer (pH 7.4)에 cytochrome c (10 mg/L), luminol(2 mg/L)을 첨가하여 사용하였고, flow-rate는 1 ml/min로 하였다. Injector를 통해 0.06% H2O2 5 ㎕ 와 0.1% test sample 5 ㎕를 injection 하였다. test sample의 항산화 효과는 0.06% H2O2의 CL intensity를 control로 하고 0.06% H2O2에 0.1% sample을 함께 injection하여 나타난 CL intensity의 감소를 비교하여 radical scavenging activity를 나타내었다. The chemiluminescence detector can be used to determine the antioxidant effect by removing reactive oxygen species (ROS) generated by hydrogen peroxide. CL intensity was measured by connecting a pump (Gilson Model 306) and an injector (Rheodyne Model 7125) to a spectrophotometer (CLA-1100, Tohoku Electronic Industry), a filter equipped photon counting type. Chemiluminescence is the reaction of cytochrome c with H 2 O 2 to produce oxygen-derived free radicals, and the product reacts with luminol to cause oxidation of luminol, resulting in chemiluminescence. At this time, free radicals are reduced by antioxidants, which act as radical scavenger, resulting in a decrease in CL intensity. The mobile phase was prepared by adding cytochrome c (10 mg / L) and luminol (2 mg / L) to 50 mM phosphate buffer (pH 7.4) made of 50% methanol. The flow rate was 1 ml / min. 5 μl of 0.06% H 2 O 2 and 5 μl of 0.1% test sample were injected through the injector. Antioxidant effect of the test sample is compared to the decrease in CL intensity appeared to injection with a 0.1% sample in 0.06% H 2 O 2 in a CL intensity as a control, and 0.06% H 2 O 2 are shown by the radical scavenging activity.
% radical scavenging activity = [A-B]/[A] x 100 % radical scavenging activity = [A-B] / [A] x 100
A : H2O2만을 injection 한 후 발생한 화학발광 A: Chemiluminescence generated after injection of H 2 O 2 only
B : H2O2 + sample(scavenger)을 injection 한 후 발생한 화학발광 B: Chemiluminescence generated after injection of H 2 O 2 + sample (scavenger)
실험 예 5 Experimental Example 5
아질산 소거작용Nitrite scavenging effect
본 발명의 기능성 제제가 발암성인 니트로사민 부산물의 형성 억제여부를 실험하였다.The functional preparation of the present invention was tested to inhibit the formation of carcinogenic nitrosamine by-products.
아질산 소거작용은 발암성 물질인 Nitrosamines 들의 생성전구물질의 활성도를 감소시켜 Nitrosamines들의 생성억제 기능을 조사하고 본 발명품 추출물에 의한 생체내에서 Nitrosamines 생성억제효과 측정을 한다.The nitrite scavenging action reduces the activity of the precursors of the nitrosamines, which are carcinogenic substances, to investigate the inhibitory function of nitrosamines and to measure the inhibitory effect of nitrosamines production in vivo by the extract of the present invention.
이 방법은 Nitrosation model system을 만들어 즉, morpholin과 NaNO2 용액을 반응시키면서 본 조성물 추출물에 의한 Nitrosation inhibition effect를 측정한다.This method creates a Nitrosation model system: morpholin and NaNO 2 While reacting the solution, the Nitrosation inhibition effect by the extract of the composition is measured.
이러한 반응에서 억제 효과의 Nitrosation반응에서 억제효과의 측정은 인체나 동물들의 위(stomach)에서 합성되는 각종 Nitrosamines들의 생성억제를 탐색함으로써 현대사회에서 큰 질병중의 하나인 암의 발생을 효과적으로 억제할 수 있는 가능성에 대한 정보를 얻을 수 있을 뿐만 아니라, 다양한 기능성을 확인할 수 있다. Inhibition of Nitrosation In this Response The measurement of the inhibitory effect in the nitrosation reaction can effectively suppress the occurrence of cancer, one of the major diseases in modern society, by searching for the inhibition of the production of various nitrosamines synthesized in the stomach of humans or animals. Not only can you get information about the possibilities, but you can also check the various functionality.
본 조성물(1.5%)를 담배 각조에 골고루 뿌린 후 건조된 담배를 피워 담배진 을 모아서 아질산염 소거능은 Kato실험(Kato, H., Lee, I.E., Chuyen, N.V., KIM, S.B. and Hayase, F.Inhibition of nitrosamine formation by nondialyable melanoidins. Agri. Bio. Cham. 51(5): 1333-1338(1987).와 Kytopoulos, S.A. Ascorbic acid and formation of N-nitroso compounds;Possible role of ascorbic acid in cancer prevention.Am.J. Clin. Nutr. 45: 1344-1350(1987)의 방법에 따라 측정하였다. 즉 1mM NaNO2용액 2mL에 각각의 본 조성물 1mL를 가하고 0.1N HCl(pH 1.2) 및 0.2M citrate buffer (pH 4.2)를 사용하여 반응 용액의 pH를 각각 1.2 및 4.2로 조정하여 총 부피가 10mL가 되도록 한 후 37℃에서 1시간 동안 반응시켰다. 반응액을 각각 1mL씩 취하고 여기에 2% actic acid 5mL와 griess시약 0.4mL를 가한 후 실온에서 빛을 차단하여 15분간 방치한 후 520nm에서 흡광도를 측정하여 잔존하는 아질산염량을 구하였다. Griess시약은 sulfanilic acid(Sigma,co.)와 naphthylamine(Sigma,co.)을 각각 1% 상당량 정량한 후 100% 초산을 첨가하여 교반 용해 시키고 30%초산이 되도록 일정량을 정용하여 사용직전에 조제하였다. 아질산염 소거율은 시료용액을 첨가한 경우와 첨가하지 않은 경우의 흡광도를 백분율로 나타내었으며 대조구로는 비타민C 10mg/100g을 사용하였다.After spreading the composition (1.5%) evenly on each cigar, smoke dried cigarettes to collect nitrite scavenging ability was Kato experiment (Kato, H., Lee, IE, Chuyen, NV, KIM, SB and Hayase, F.Inhibition of nitrosamine formation by nondialyable melanoidins.Agri.Bio.Cham. 51 (5): 1333-1338 (1987). and Kytopoulos, SA Ascorbic acid and formation of N-nitroso compounds; Possible role of ascorbic acid in cancer prevention.Am. J. Clin. Nutr. 45: Measured according to the method of 1344-1350 (1987), ie, 1 mL of each of the compositions was added to 2 mL of 1 mM NaNO 2 solution and 0.1 N HCl (pH 1.2) and 0.2 M citrate buffer (pH 4.2). ), The pH of the reaction solution was adjusted to 1.2 and 4.2, respectively, so that the total volume was 10 mL, and the reaction was carried out for 1 hour at 37 ° C. 1 mL of the reaction solution was taken, and 5 mL of 2% actic acid and griess reagent were added thereto. After adding 0.4mL, the solution was blocked at room temperature for 15 minutes and the absorbance was measured at 520nm. Griess reagent quantified 1% equivalents of sulfanilic acid (Sigma, co.) And naphthylamine (Sigma, co.), Respectively, and added 100% acetic acid to stir and dissolve it. The nitrite scavenging rate was expressed as the percentage of absorbance with and without sample solution, and vitamin C 10mg / 100g was used as a control.
SA(%) = (1 - A-B/B) X 100 SA (%) = (1-A-B
SA : Nitrite scavenging ability SA: Nitrite scavenging ability
A : Absorbance of 1mM NaNO2 added sample after standing for 1 hourA: Absorbance of 1mM NaNO 2 added sample after standing for 1 hour
B: Absorbance of NaNO2 B: Absorbance of NaNO 2
C : Absorbance of control C: Absorbance of control
실험결과는 본 조성물의 기능성 제품에 대한 아질산염 소거율을 조사한 결과는 표4와 같다. 본 조성물에 대한 기능성 제품은 pH 1.2의 조건에서 전체적으로 55.75~99.86%로 가장 높은 소거율을 나타냈으며 pH 4.2에서는 10.25~34.22%로 pH가 증가할수록 소거율이 크게 감소하는 경향을 나타내었다. Nitrosamine생성 최적pH 는 2.5~3.0으로 pH가 높아질수록 감소하는 것으로 보고한 결과와도 동일한 경향을 나타내었다.Experimental results are the results of examining the nitrite scavenging rate for the functional product of the composition is shown in Table 4. The functional product for this composition showed the highest scavenging rate as a whole at 55.75 ~ 99.86% under the condition of pH 1.2, and the scavenging rate was significantly decreased as the pH was increased to 10.25 ~ 34.22% at pH 4.2. The optimum pH for nitrosamine production was 2.5 ~ 3.0, which showed the same tendency to decrease with increasing pH.
위장 내(낮은 pH조건에서) 또는 담배연기에서 nitrosamine이 쉽게 형성되므로 낮은 pH에서의 아질산염 소거율이 큰 것은 nitrosamine 형성을 효과적으로 억제하는 것으로 판단된다. 대조군으로 사용한 vitamine C, 10mg의 아질산염 소거율은 pH1.2에서 98.93%였으며, pH4.2에서는92.91%로 나타났다. Since nitrosamine is easily formed in the gastrointestinal (low pH) or tobacco smoke, the high nitrite scavenging rate at low pH seems to effectively inhibit nitrosamine formation. The nitrite scavenging rate of vitamine C and 10 mg used as a control group was 98.93% at pH 1.2 and 92.91% at pH 4.2.
표 4Table 4
실험 예 6 Experimental Example 6
본 조성물에 의한 비장세포 증식효과Splenocyte proliferation effect by the present composition
NO는 최근 약리 및 독성 작용에 관여하는 새로운 생체조절 물질로 발암과 고 혈압, 지혈, 면역반응. 뇌독성은 물론 근세포나 간세포, 신경세포등의 고유 작용을 중화시키는 표적으로 작용한다. 하지만 NO가 쌍을 이루지 못한 전자를 갖는 다른 종들과 반응할 경우 더욱 독성이 강한 2차 물질을 생성, 치명적인 조직 손상을 일으키는 직접적인 원인이 되기도 한다.NO is a new bioregulator that is recently involved in pharmacological and toxic effects. Brain toxicity, of course, acts as a target to neutralize the intrinsic action of myocytes, hepatocytes, neurons. However, when NO reacts with other species with unpaired electrons, it also produces a more toxic secondary, which is a direct cause of fatal tissue damage.
일반적으로 대식 세포는 크게 3가지의 항 미생물 작용이 항진된다.In general, macrophages have three major antimicrobial activities.
첫째는 세포내 lysosome에 들어 있는 여러 가지 가수 분해 효소의 증가이고,First is the increase in various hydrolytic enzymes contained in intracellular lysosomes.
둘째는 NADH oxidase의 활성에 의한 ROI의 생성이며,Second is the generation of ROI by NADH oxidase activity,
셋째는 NO의 생성이다.Third is the production of NO.
그러나 과량의 ROI 및 NO는 조직을 손상시키고 염증을 유발한다. 따라서 이 두 가지 활성 물질의 생성은 조절될 필요성이 있으며, 여러 연구에 의하면 NO와 ROI는 동시에 생성되거나 어느 한쪽에 의해서 생성이 촉진되기도 한다Excess ROI and NO, however, damage tissues and cause inflammation. Therefore, the production of these two active substances needs to be regulated, and studies have shown that NO and ROI are produced simultaneously or promoted by either.
본 발명의 시험은 마우스 대식세포인 RAE264.7을 well당 1X105개 세포를 분취하고 37℃ CO2배양기에서 2시간 동안 배양하여 부착되지 않는 죽은 세포를 제거하고, 본 조성물을 농도별로 단독 또는 LPS(100ng/ml)와 혼합하여 처리하고 24시간 배양했다. 배양 종료 후 배양 상등액 중의 nitrite(NO의 안정한 수화합물)를 NaNO2를 Standard로 하여 Griess시약을 이용하여 정량하였다.In the test of the present invention, RAE264.7, a mouse macrophage, was collected at 1 × 10 5 cells per well, and cultured for 2 hours in a 37 ° C. CO 2 incubator to remove non-attached dead cells. (100 ng / ml) was mixed and treated and incubated for 24 hours. After completion of the culture, nitrite (a stable aqueous compound of NO) in the culture supernatant was quantified using Griess reagent using NaNO 2 as a standard.
표 5. Inhibition effect of L on NO production in RAW 264.7(Each value represents mean ± S.D. of triplicates.Table 5. Inhibition effect of L on NO production in RAW 264.7 (Each value represents mean ± S.D. of triplicates.
실험 결과는 위의 표에서 본 바와 같이 본 조성물은 동물세포에 대하여 독성이 없으며(1mg/ml농도까지 실험) mitogen(LPS. ConA)보다는 약하지만 마우스 면역세포(비장세포)의 증식을 촉진시키며 알려진 NO inhibitor(NMMA, Polymicin B)보다는 약하지만 RAW의 NO 생성을 저해하며(Inos(생 합성효소) 저해 or NO의 직접 감소.) In vitro 실험결과 면역세포의 활성화를 유도하고, 생체 내 면역활성이 있다.Experimental results show that the composition is not toxic to animal cells (experimental to 1 mg / ml), as shown in the table above, weaker than mitogen (LPS. ConA), but promotes the proliferation of mouse immune cells (splenocytes). Although weaker than NO inhibitors (NMMA, Polymicin B), they inhibit NO production in RAW (inhibition of Inos or direct reduction of NO). In vitro experiments induce the activation of immune cells and increase the immune activity in vivo. have.
실험 예 7 Experimental Example 7
AMES TESTAMES TEST
담배연기 속에는 약 4,000여종의 독성물질이 들어 있다. 이 독성물질에 대하여 얼마만큼의 독성을 경감시키는지 알아보기 위하여 아래의 실험방법(AMES TEST)에 의하여 실험한 결과이다. Tobacco smoke contains about 4,000 toxic substances. In order to find out how much to reduce the toxicity of this toxic substance, the experiment was conducted by the following test method (AMES TEST).
항돌연변이성 유발을 평가하기 위하여, B(a)P에 의하여 돌연변이를 유발시키고 추출물에 의한 억제 작용을 검증한다. Model system은 Aflation B1과 benzo(α)Pyrene(B(a)P), 그리고 몇 가지 Nitrosamines 화합물을 이용하여 mutagencity를 또한 Smoke condensate(담배 진)를 농도별로 첨가하여 위와 같은 방법으로 돌연변이 유발억제 현상을 조사하는 것이다. To assess antimutagenic induction, mutations are induced by B (a) P and the inhibitory action by the extract is verified. In the model system, mutagencity is added by using concentrations of Aflation B 1 , benzo (α) Pyrene (B (a) P), and some Nitrosamines, and smoke condensate is added to each concentration. To investigate.
☞측정목적 : Salmonella균을 이용한 Ames Test는 이 물질 대사에 주된 역할 을 하는 microsomal mixid function oxidase system에 의해 대사되는 과정에서 mutagenic activity(돌연변이성)를 나타내는지를 확인하는 방법으로, 이를 이용하여 Model system을 적용하여 추출물에 의한 억제현상을 조사한다. ☞ Purpose: Ames test using Salmonella bacteria is a method to check whether it shows mutagenic activity during metabolism by microsomal mixid function oxidase system that plays a major role in metabolism. Investigate the inhibition effect by extract.
표6. 본 조성물(X±SD)의 AMES Test의 결과.Table 6. Results of the AMES Test of this composition (X ± SD).
실험결과는 담배연기 속에 독성물질에 대하여 얼마만큼의 독성을 경감시키는지 알아보기 위하여 실험 방법(AMES TEST)에 의하여 실험한 결과이다. Experimental results It is the result of experiment by the test method (AMES TEST) to find out how much toxic substances are reduced in the tobacco smoke.
Smoke condensate(담배 진)의 농도에 따라서 mutagenic activity(돌연변이성) 및 담배 연기의 독성물질인 특히 발암성 물질인 암을 일으키는 nitrosamines에 대하여 담배연기의 경감효과가 얼마나 있는지 실험한 결과 각 농도에 따라서 독성경감효과가 있는 것으로 나타났다.According to the concentration of smoke condensate, we tested the effects of cigarette smoke reduction on nitrosamines that cause mutagenic activity and toxic substances of tobacco smoke, especially carcinogenic cancers. It was shown to be mitigating.
실험 예 8 Experimental Example 8
골수미핵시험Bone marrow nuclear test
본 조성물의 마우스 골수 미핵 시험의 방법에 의해 염색체의 손상 여부를 시 험하였다.Chromosomal damage was examined by the method of mouse bone marrow micronucleus test of the composition.
표7. 마우스 골수 미핵시험 결과Table 7. Mouse bone marrow nucleus test result
시험결과는 수컷과 암컷의 골수 미핵 세포들의 Macronucleus 시험의 결과는 1회 복용량 범위에서 본 조성물을 5~20g/kg 투여한 결과 마우스의 골수미핵 세포들의 염색체 이상 반응은 없었다.The results of the macronucleus test of male and female bone marrow micronucleus cells showed that the chromosomal aberrations of the myeloid nucleus cells of the mouse were not observed after 5-20 g / kg of the composition was administered in a single dose range.
실험 예 9 Experimental Example 9
작은 쥐 정자기형시험Small Rat Spermatology Test
본 조성물의 작은쥐 정자기형시험을 하여 정자수의 손상여부를 조사하였다.The small rat sperm malformation test of the present composition was examined to determine whether sperm count was damaged.
표8. 작은쥐 정자기형시험Table 8. Small mouse sperm malformation test
시험결과는 본 조성물 1회 복용량 5~20g/kg 투여한 결과 마우스 정자수의 이상 변화는 없었다.The test results showed that there was no abnormal change in mouse sperm count when the composition was administered in a dose of 5-20 g / kg.
실험 예 10 Experimental Example 10
2-Aminofluorene (2-AF)시험2-Aminofluorene (2-AF) Test
2-AF는 세계에서 알려져 있는 가장 강한 화학적인 발암 물질들이다. 2-Aminofluorene의 억제한 결과는 다음과 같다.2-AF is the strongest chemical carcinogen known in the world. Inhibition of 2-aminofluorene is as follows.
표9. 2-Aminofluorene(2-AF)의 돌연변이 유발력에서 본 발명품의 영향.Table 9. Influence of the invention on mutagenicity of 2-Aminofluorene (2-AF).
시험결과 2-AF가 활성화되는데 긍정적인 목적은 돌연변이의 원인으로서 본 조성물은 대단히 2-AF의 돌연변이 유발력을 제지할 수 있었다. 그리고 1회 복용량 120mg/plate에서, 본 조성물은 완전히 2-AF의 돌연변이 유발성 영향을 제거할 수 있었다. As a result, the positive purpose of activating 2-AF was to cause mutation, and the composition was able to significantly inhibit the mutagenicity of 2-AF. And at a single dose of 120 mg / plate, the composition was able to completely eliminate the mutagenic effects of 2-AF.
실험 예 11 Experimental Example 11
담배의 TAR중 NNN. NAT. NNK. B(a)P분석NNN in TAR of tobacco. NAT. NNK. B (a) P Analysis
대기중에는 자동차 배기가스, 공장굴뚝, 주택이나 건물의 난방 등에서 발생 하는 매연과 함께 수백 종의 화학물질들이 다수 포함돼 있다. 그중에 벤조피렌은 폐암을 일으키는 물질로 알려져 있으며, 특히 흡연으로 인한 문제가 현재 제기되고 있다.The atmosphere contains hundreds of chemicals, along with smoke from automobile exhaust, factory chimneys, and heating in houses and buildings. Among them, benzopyrene is known as a substance causing lung cancer, and in particular, a problem due to smoking has been raised.
흡연으로 인한 니코틴이 니코틴 유도체인 NNK, NNN, NAT로 전환되는 것보다 코티닌으로 빠르게 대사되는 것이 흡연으로 인한 피해를 줄이고, 또한 Benzo(a)pyren을 줄임으로써 궁극적으로 발암물질을 효과적으로 억제할 수 있다.The faster metabolism of nicotine from smoking than the conversion of nicotine into the nicotine derivatives NNK, NNN and NAT can reduce the damage caused by smoking and ultimately inhibit carcinogens by reducing Benzo (a) pyren. .
본 조성물을 담배에 첨가하여 담배연기를 측정한 결과이다.It is the result of measuring tobacco smoke by adding this composition to tobacco.
1. 시약1. Reagent
1.1 표준물질 1.1 Standard
NNN, NAT, NNK, B(a)P(2000㎍/㎖, Supelco, USA)를 약 1.0∼40.0ng/㎖의 농도범위로 희석하여 사용하였다.NNN, NAT, NNK, and B (a) P (2000 µg / ml, Supelco, USA) were used diluted to a concentration range of about 1.0 to 40.0 ng / ml.
2. 기기 및 장치2. Appliances and Devices
2.1 기체 크로마토그래피
사용한 기체크로마토그래피는 Hewlett Packard사(미국) 6890 Plus에 Detector 는 Flame Ionized Detector와 Mass Selective Detector, HP 5973을 사용하였다.2.1 Gas Chromatography
The gas chromatography used was Hewlett Packard (USA) 6890 Plus Detector used Flame Ionized Detector, Mass Selective Detector, HP 5973.
삭제delete
2.2 자동흡연장치
자동흡연장치는 Heinr. Borgwaldt(독일)의 20-port 흡연기를 사용하였다.2.2 Automatic Smoking Device
Automatic smoking device is Heinr. A 20-port smoker from Borgwaldt (Germany) was used.
삭제delete
3. 분석방법3. Analysis method
3.1. 시험담배 3.1. Test cigarette
3.1.1중국천진연초제조창에서 본 조성물을 첨가하여 제조한 SAMPLE담배, 3.1.1 SAMPLE cigarette manufactured by adding this composition in Tianjin tobacco production window,
3.1.2 중국천진연초제조창에서 제조한 HANDA담배(대조담배)3.1.2 HANDA Tobacco Manufactured at Tianjin Tobacco Manufacturing Window, China
3.2. 시험담배 제조3.2. Cigarette production
본 조성물 100mg에 증류수 2ml을 넣어 본 발명품을 잘 용해하여 각초 담배잎 20g에 골고루 살포한후 50℃에서 24시간 건조하였다.2 ml of distilled water was added to 100 mg of the present composition, and the present invention was dissolved well, evenly sprayed onto 20 g of tobacco leaves, and dried at 50 ° C. for 24 hours.
3.3. 담배의 Tar중 NNN. NAT. NNK. Benzo(a)pyrene)분석3.3. NNN of Tar in Tobacco. NAT. NNK. Benzo (a) pyrene) Assay
3.3.1 연소조건3.3.1 Combustion conditions
각각의 시험 담배를 제조하여 CORESTA 표준조건으로 연소하였다. 연소조건은 흡연부피 35±0.5ml, 흡연시간 2.0초, 흡연주기 60초이다. 꽁초길이는 필터가 부착된 팁페이파 길이 +3mm로 조절하였다.Each test cigarette was prepared and burned to CORESTA standard conditions. Combustion conditions were 35 ± 0.5ml of smoking volume, 2.0 seconds of smoking time and 60 seconds of smoking cycle. The length of the butts was adjusted to the length of the tip paper with filter +3 mm.
흡연프로필은 (puff profile)은 ISO 3308을 만족하는 종모양(bell shape)을 유지하도록 하였다.The smoking profile was designed to maintain a bell shape that meets ISO 3308.
3.2.2 담배의 Tar중 NNN(N'-nitrosonor nicotine) 3.2.2 N'-nitrosonor nicotine in tar
NAT(N'-nitrosoanatabine). N'-nitrosoanatabine (NAT).
NNK(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone). NNK (4- (methylnitrosamino) -1- (3-pyridyl) -1-butanone).
Benzo(a)pyrene(B(a)P)의 정량분석 결과.Quantitative analysis of Benzo (a) pyrene (B (a) P).
표10. 정량분석결과 (단위 : ng/개피)
Table 10. Quantitative Analysis Results (Unit: ng / bare)
4. 시험결과4. Test result
담배의 Tar중 NNN, NAT, NNK, B(a)P시험결과 CONTROL(대조담배)군보다 SAMPLE (본조성물 2%추가)군이 평균 70.723%가 감소되었다.Among tobacco tars, NNN, NAT, NNK, and B (a) P test resulted in an average 70.723% reduction in SAMPLE (2% additional composition) than the CONTROL group.
실험 예 12 Experimental Example 12
본조성물이 mouse splenocyte의 proliferation에 미치는 영향(면역력시험)Effect of this composition on proliferation of mouse splenocyte (immunity test)
SplenicSplenic cellcell cultureculture 방법Way
3주령의 ICR mouse로부터 적출한 비장을 생리식염수로 세척하여 complete RPMI 1640 media에서 비장세포를 분리하였다. 분리된 비장세포를 96well에 2 x 105 cells/ml로 분주하여 Con A, LPS 등의 stimulator와 함께 배양하면서 각각 다른 농도의 조성물을 처리하여 37℃, 5% CO2 incubator에서 이틀간 배양한 후 alarmar blue를 20㎕/well로 처리하여 micro plate reder로 흡광도를 측정하였다. Spleens from three-week-old ICR mice were washed with physiological saline to separate splenocytes from complete RPMI 1640 media. The isolated splenocytes were dispensed at 96 x 2 wells at 2 x 10 5 cells / ml and incubated with stimulators such as Con A and LPS, and treated with different concentrations of the composition at 37 ° C and 5% CO 2. After incubation in the incubator for two days, the absorbance was measured using a microplate reder by treating alarmar blue with 20µl / well.
* 본 조성물의 농도 : 20, 50, 100, 200 ug/ml * Concentration of this composition: 20, 50, 100, 200 ug / ml
* 모든 실험은 클린벤치에서 하였으며 media를 비롯한 모든 샘플은 여과(22㎛) 하여 세포에 처리하였다. * All experiments were performed in a clean bench, and all samples including media were filtered (22 μm) and treated to cells.
* micro plate reder : measurment 570㎚, referance 600㎚에서 측정 * micro plate reder: measured at measurment 570 nm, referance 600 nm
** Alamar Blue assay : alamar blue dye는 무독성으로 세포의 활성에 의해 대사 되어 파란색으로 변하는 성질을 이용한 cytotoxity 측정실험법. micro plate reder로 측정한 OD값이 낮을 경우 cell proliferation이 감소된 것으로 평가함. ** Alamar Blue assay: Alamar blue dye is a non-toxic cytotoxity assay that uses metabolic properties of cells to turn blue. When the OD value measured by the micro plate reder is low, the cell proliferation is estimated to be reduced.
시험결과는 아래와 같다.The test results are as follows.
Con A를 stimulus로 하여 이틀 배양후 alamar blue를 투입.Two days of incubation with Con A as stimulus, followed by alamar blue.
표10. 32시간이 경과한 상태의 본 조성물에 대한 결과이다.Table 10. It is the result about this composition of the state which passed 32 hours.
실험 예 13 Experimental Example 13
동물실험(PLASMA)결과 Results of Animal Testing (PLASMA)
1.실험방법 : 3주령의 SD-rat 을 Normal, Nicotin, Nicotine + 본 발명품(n=7) 의 그룹으로 나누어 사육 후 7주령에 희생시켰다.1. Experimental Method: SD-rat at 3 weeks of age was divided into groups of Normal, Nicotin, and Nicotine + the present invention (n = 7) and sacrificed at 7 weeks of age after breeding.
Normal (n=6) : 자유식이 Normal (n = 6): Free expression
Nicotine (n=8) : nicotine 4mg/kgBW 경구투여 + 200mg/kgBW 생리식염수 복강투여 Nicotine (n = 8): nicotine 4mg / kgBW oral administration + 200mg / kgBW physiological saline intraperitoneal administration
Nicotine + 본 조성물 (n=7) : nicotine 4mg/kgBW 경구투여 + 200mg/kgBW 본 조성물 복강투여 Nicotine + composition (n = 7): nicotine 4mg / kgBW oral administration + 200mg / kgBW this composition intraperitoneally
2. Plasma 분석 2. Plasma Analysis
희생시킨 동물의 동맥에서 혈액을 채취하여 응고 방지를 위해 EDTA 처리 하였다. 채취된 혈액은 3,000rpm에 10분간 원심분리하여 혈청을 분리한 후 분석할 때 까지 -70℃에서 보관하였다. Blood was collected from the arteries of the sacrificed animals and treated with EDTA to prevent coagulation. Collected blood was centrifuged at 3,000 rpm for 10 minutes to separate serum and stored at -70 ℃ until analysis.
1) Total Cholesterol : 혈중 총콜레스테롤 측정 키트(Wako, Japan)를 사용하여 UV-VIS Spectrophotometer 505nm에서 흡광도를 측정하여 정량 하였다. 1) Total Cholesterol: Using the blood total cholesterol measurement kit (Wako, Japan), absorbance was measured and measured by UV-VIS Spectrophotometer 505nm.
2) Triglyceride : 혈중 중성지방 측정 키트(Wako, Japan)를 사용하여 UV- VIS Spectrophotometer 410nm에서 흡광도를 측정하여 정량 하였다. 2) Triglyceride: Using a blood triglyceride measurement kit (Wako, Japan), absorbance was measured on the UV-VIS Spectrophotometer at 410 nm.
3. 지질과산화 함량 측정 (TBARS)3. Determination of Lipid Peroxidation Content (TBARS)
4주간 Nicotine 및 본조성물 투여 후 diethyl ether로 마취시켜 간을 적출하였다. 적출한 간은 분석할 때 까지 -70℃에서 보관하였다. After administration of Nicotine and this composition for 4 weeks, the liver was extracted by anesthesia with diethyl ether. The isolated liver was stored at -70 ° C until analysis.
간 1g을 100mM Tris-HCl, pH 7.4 buffer로 homogenate 한 후 TBA 정색시약을 첨가하여 535nm에서 생성된 TBARS 함량을 정량 분석하였다.After 1 g of liver was homogenated with 100 mM Tris-HCl, pH 7.4 buffer, TBA color reagent was added to quantitatively analyze the TBARS content generated at 535 nm.
표11. 실험결과Table 11. Experiment result
TBARS-(ThioBarbutic Acid -Recative Substance)란.What is TBARS- (ThioBarbutic Acid -Recative Substance).
TBA 시약과 반응하는 MDA(MalonDiAldehyde-지질과산화 생성물)를 측정하여 지질 과산화정도 측정 Determination of lipid peroxidation by measuring MDA (MalonDiAldehyde-lipid peroxidation product) reacting with TBA reagent
실험 예 14 Experimental Example 14
본 조성물의 랫드를 이용한 단회경구투여독성시험Single Oral Dose Toxicity Test Using Rats of the Composition
1) 시험목적 : 본조성물의 랫드에 있어서 단회경구투여에 의한 독성을 조사하기 위하여 실시한다.1) Purpose: To investigate the toxicity by single oral administration in rats of this composition.
2) 시험방법 : 식품의약품안전청 고시 제1999-61호(1999년 12월 22일) '의약품등의 독성시험 기준'에 준하여 수행하였다.2) Test method: This test was conducted in accordance with Korean Food and Drug Administration Notification No. 1999-61 (December 22, 1999), 'Toxicity Test Standards for Drugs'.
3)동물사육실 : 중앙기기센터 SPF 실험동물실3) Animal Breeding Room: SPF Laboratory Animal Center, Central Equipment Center
4) 시험물질의 보관 : 본 시험에 사용한 시험물질은 냉장보관하였다.4) Storage of test substance: The test substance used in this test was refrigerated.
1. 요약1. Summary
본 조성물의 랫드에 있어서 단회 경구투여에 의한 독성을 조사하기 위하여 암수 공히 부형제 대조군과 시험물질 용량으로 5마리의 Sparague-daweley(SD) 계통 랫드에 투여하고 2주간의 사망률, 일반증상, 체중변화 및 부검소견을 관찰하였다.In order to investigate the toxicity by single oral administration in rats of the present composition, male and female were administered to five Sparague-daweley (SD) strain rats in excipient control and test substance doses for 2 weeks of mortality, general symptoms, weight change and Autopsy findings were observed.
(1) 시험 전 기간 동안 사망동물은 관찰되지 않았다.(1) No dead animals were observed during the entire test period.
(2) 일반증상에서도 시험물질의 투여와 관련된 어떠한 이상증상도 관찰되지 않았다.(2) No abnormal symptoms related to administration of test substance were observed in general symptoms.
(3) 시험 전 기간을 통한 경구투여에 있어서 암수 모두에서 각 군 간의 유의성있는 체중변화는 인정되지 않았다.(3) Significant body weight change between groups was not recognized in both male and female in oral administration through the entire study period.
(4) 부검소견에서도 시험물질의 투여와 관련된 독성학적인 이상소견이 관찰되지 않았다.(4) There were no toxicological abnormalities associated with the administration of test substance in autopsy findings.
(5) 결과(5) results
이상의 시험 결과로부터 본 시험조건하에서 본 조성물의 랫드 암수에 있어서 단회 경구투여시 시험 물질과 연관된 어떠한 특이할 만한 독성증상도 관찰되지 않아 본 조성물의 랫드에서의 최소치사량(MLD)은 2,000㎎/㎏을 상회하는 것으로 사료되었다.From the above test results, no unusual toxicity symptoms associated with the test substance were observed in the male and female rats of the composition under the test conditions. Therefore, the minimum lethal dose (MLD) in the rat of the composition was 2,000 mg / kg It was thought to be higher than that.
2. 본 조성물 및 부형제 대조 물질2. Compositions and Excipient Controls
(1) 시험물질(1) Test substance
1) 명 칭 : 복합한약재 추출물 1) Name: Complex Herbal Extract
2) 입수량 : 20g(용기포함)2) Quantity of water: 20g (including container)
3) 입수일 : 2004년 2월 28일3) Date of acquisition: February 28, 2004
4) 외관 및 성상 : 갈색 분말4) Appearance and appearance: brown powder
5) 보관조건 : 냉장보관5) Storage condition: Refrigerated storage
(2) 부형제 대조물질(2) excipient control substances
1) 명 칭 : 멸균 주사용수1) Name: sterile water for injection
2) 제조자 : 대한약품공업주식회사2) Manufacturer: Korea Pharmaceutical Industry Co., Ltd.
3) 제조번호 : 04D3F213) Manufacturing Number: 04D3F21
3. 재료 및 방법3. Materials and Methods
(1) 시험계(1) test system
1) 종 및 계통1) Species and strains
SD(Spraue-dawley) 계통의 특정병원균 부재(SPF) 랫드SPF rats of Spraue-dawley (SD) strain
2) 공급원2) Source
(주)오리엔트Orient Co., Ltd.
주소 : 경기도 가평군 북면 목동리 699-13Address: 699-13, Mokdong-ri, Buk-myeon, Gapyeong-gun, Gyeonggi-do
3) 시험계의 선택이유3) Reason for selection of test system
본 시험에 사용된 랫드는 독성시험에 적당한 실험동물로서 일반 독성시험에 널리 사용되고 있다. 또한 본 계통의 랫드는 풍부한 시험기초자료가 축적되어 있어서 시험결과를 해석하고 평가할 때에 이러한 자료를 이용할 수 있기 때문이다.Rats used in this study are suitable for toxicity test and are widely used for general toxicity test. In addition, the rats of this system have accumulated abundant test basis data and can use these data when interpreting and evaluating the test results.
4) 주령 및 체중범위4) Age and weight range
입수시 주령 : 암수 각 4주령Receipt of age: 4 weeks of age and sex
입수시 동물수 : 암수 각 17마리Number of Animals: 17 Male and Female
입수시 체중 : 수컷 (80-90g), 암컷 (70-80g)Body weight at arrival: Male (80-90g), Female (70-80g)
투여개시시 주령 : 암수 각 5주령Age at start of administration: 5 weeks for male and female
투여개시시 동물수 : 암수 각 5마리Number of animals at start of administration: 5 male and female
5) 검역 및 순화5) Quarantine and Purification
입수시 공급처에서 제공한 시험계의 병원체검사 성적서를 참고로 하여 입수동물의 검수 ·검역을 실시 하였으며 동물입수 후 7일간 시험을 실시하는 동물실 내에서 순화시켰다. 순화기간 중 일반증상을 관찰하여 건강한 동물만을 시험에 제공하였다.Upon receipt, the animals were inspected and quarantined with reference to the pathogen test report provided by the supplier. The animals were purified in the animal room, which was tested for 7 days after the animals were obtained. General symptoms were observed during the acclimation period and only healthy animals were given to the test.
(2) 사육환경(2) Breeding environment
1) 환경조건1) Environmental conditions
본 시험은 온도 23 ±3℃, 상대습도 55 ±15%, 환기횟수 10-20회/h, 조명시간 12hr(08:00점등 ~ 20:00소등) 및 조도 150~300Lux로 설정된 대구카톨릭대학교 SPE 실험동물실 GLP사육실에서 수행 되었다.Daegu Catholic University SPE with temperature 23 ± 3 ℃, relative humidity 55 ± 15%, ventilation frequency 10-20 times / h, lighting time 12hr (08:00 to 20:00 off) and illuminance 150 ~ 300Lux Laboratory animals were performed in the GLP nursery.
2) 사육환경 모니터링2) Monitoring of breeding environment
시험기간 중 동물실의 온.습도는 컴퓨터시스템을 이용한 자동 온.습도측정기에 의하여 매 시간마다 측정되었으며, 환기횟수 및 조도 등의 환경조건은 정기적으로 측정되었다. 시험기간중에 환경의 이상은 관찰되지 않았다.During the test, the temperature and humidity of the animal room were measured every hour by an automatic temperature and humidity meter using a computer system, and the environmental conditions such as the number of times of ventilation and illuminance were measured regularly. No environmental abnormalities were observed during the test period.
3) 사육상자, 사육밀도 및 사육상자의 식별3) Identification of breeding box, breeding density and breeding box
동물은 스테인레스망 사육상자(215W×360L×200Hmm)에 순화 및 관찰기간 모두 5마리씩 사육하였다. 사육상자는 시험번호 및 동물번호를 기입한 개체식별카드를 부착하여 식별하였다.Animals were bred in stainless net cages (215W × 360L × 200Hmm) for 5 rats in both the periods of acclimation and observation. Breeding boxes were identified by affixing individual identification cards containing test and animal numbers.
4) 사료 및 물의 급여방법4) Feeding method of feed and water
사료는 폴라스인터네셔날로부터 공급받은 방사선조사로 멸균된 시험동물용 고형사료(Harlan Co.,Ltd. 미국)를 자유섭취시켰다.The feed was freely ingested with sterilized test animal solid feed (Harlan Co., Ltd., USA) supplied by Polar International.
(3) 투여량 및 시험군의 구성(3) Dosage and composition of test group
예비시험에서 투여용량을 증류수, 2000mg/kg, 500mg/kg, 50mg/kg, 5mg/kg을 정하여 각 용량별 시험군은 암수 2마리씩 투여하였다. 이틀간의 관찰결과 아무런 유익한 독성증상이 없어 2000mg/kg 체중에서 암수 각 5마리씩 투여하는 본 시험을 시행하였다.In the preliminary test, the dose was set to distilled water, 2000 mg / kg, 500 mg / kg, 50 mg / kg, and 5 mg / kg. Two days of observation showed no beneficial toxicity, so this study was administered with five male and female females at 2000 mg / kg body weight.
4. 결과4. Results
(1) 사망동물 및 최소취사량(1) Death animals and minimum cooking quantity
전 시험기간 동안 시험군에서 사망동물은 관찰되지 않았다. 따라서 본 시험에서 랫드의 최소취사량 한계용량인 2000mg/kg을 상회하는 것으로 관찰되었다.No dead animals were observed in the test group during the entire trial. Therefore, it was observed that the rat exceeded the minimum dose limit of 2000 mg / kg in rats.
(2) 일반증상(표12)(2) General symptoms (Table 12)
전 시험 기간 동안 모든 군에서 아무런 증상이 관찰되지 않았다.No symptoms were observed in all groups during the entire trial.
(3) 체중변화(표13)(3) Weight change (Table 13)
암수 체중변화에 있어서 이상징후가 관찰되지 않았다.No abnormal symptoms were observed in male and female body weight changes.
(4) 부검소견(4) autopsy findings
사망과 이상징후 그리고 체중변화에 있어서 특이점이 없어 부검은 실시하지 않았다.An autopsy was not performed because there were no specificities in death, abnormal symptoms, and weight changes.
표 12. Incidence of clinical signs in male rats after single oral administration of herbal extracts(group summary)Table 12. Incidence of clinical signs in male rats after single oral administration of herbal extracts (group summary)
; Number of animals with the sign/Number of animals examined; Number of animals with the sign / Number of animals examined
표 13. Body weight change in male rats after single oral administration of Herbal extracts(group summary)Table 13. Body weight change in male rats after single oral administration of Herbal extracts (group summary)
이상의 실험에서 확인되는 바와 같이 본 발명의 조성물은 인체 내의 유해물질 분해 및 배출에 탁월한 효능을 가진다. 따라서 본 발명의 조성물은 담배흡연에 의한 니코틴중독이나 또는 기타 유해물질의 해독제로서 대단히 유용하다.As confirmed in the above experiments, the composition of the present invention has an excellent effect on the decomposition and release of harmful substances in the human body. Therefore, the composition of the present invention is very useful as an antidote for nicotine poisoning or other harmful substances by tobacco smoking.
본 발명의 조성물은 이를 정제, 산제, 액제, 시럽제, 캡슐제, 주사제 등과 같은 통상의 식품이나 의약품에서 사용되는 제제형태로서 사용될 수도 있으며, 또는 음료수나 차등에 혼합하여 제조하여 섭취할 수도 있으며, 이는 이 분야에 통상의 지식을 가진 사람에게는 매우 쉬운 일이다.The composition of the present invention may be used as a preparation form used in conventional foods or pharmaceuticals, such as tablets, powders, liquids, syrups, capsules, injections, etc., or may be prepared by ingesting it in a drink or tea, It is very easy for someone with ordinary knowledge in this field.
본 발명의 조성물은 음료나 과자류, 동물이나 어류의 사료, 또는 구강치약, 비누에 첨가하여 사용될 수도 있다.The composition of the present invention may be used in addition to beverages, confectionery, animal or fish feed, oral toothpaste, soap.
본 발명의 조성물은 기존에 식품 또는 의약품으로 오랫동안 사용되어오고 있는 성분들이며, 따라서 독성은 거의 없는 것으로 판명된 성분들이다.The compositions of the present invention are ingredients that have been used for a long time as food or medicine, and therefore are ingredients that have been found to have little toxicity.
상기 실험 예에서도 명백한 바와 같이, 본 발명의 조성물은 흡연으로 인한 인체 내의 유독성분을 해독하는 기능성 제제와 니코틴의 분해를 가속화시키고, 발암성의 니트로소-화합물과 벤조파이렌의 형성을 억제한다. 또한 담배에 의한 발암물질 형성을 저해하고, 항산화효과를 나타낼 뿐만 아니라 NNK,NNN,NAT와 벤조피렌에 의한 돌연변이능을 억제시키고, 폐암발생율을 억제시킨다.As is evident in the above experimental example, the composition of the present invention accelerates the decomposition of nicotine and functional agents that detoxify toxic components in the human body due to smoking, and inhibits the formation of carcinogenic nitroso-compounds and benzopyrene. In addition, it inhibits the formation of carcinogens by tobacco, exhibits antioxidant effects, inhibits mutagenic activity by NNK, NNN, NAT and benzopyrene, and suppresses lung cancer incidence.
따라서 본 발명의 조성물은 흡연으로 인한 인체 내의 유독성분을 감소 또는 제거하며,흡연으로 인한 피해를 저하시키고, 또한 혈액중의 니코틴 양을 저하시키므로 흡연으로 인하여 발생한 인체 내의 유독 성분을 감소 또는 제거함으로써 각종 질병들을 미연에 예방할 수 있다.Therefore, the composition of the present invention reduces or eliminates toxic components in the human body due to smoking, reduces damage caused by smoking, and also reduces the amount of nicotine in the blood, thereby reducing or eliminating toxic components in the human body caused by smoking. Diseases can be prevented beforehand.
더욱이, 본 발명의 조성물은 음식물 또는 기능성제품으로 제제화된 식품으로서 섭취하게 되므로 인체 내의 흡연 유독성분을 감소 또는 제거하며, 끽연 습관을 중단하거나 끽연시 다른 물품을 사용하거나 여분의 동작을 추가할 필요가 없다.Moreover, the composition of the present invention is consumed as a food or a food formulated as a functional product, so as to reduce or eliminate smoking toxic components in the human body, it is necessary to stop smoking habits, use other items or add extra actions when smoking. none.
따라서 현대사회에서 크게 문제시되고 있는 각종유해물질의 광범위한 오염으로 인한 면역능력 저하와 방어능력을 향상시키고 각종유해물질의 독성감소및 기능성 식품첨가물과 담배첨가물에 적용하여 사용할 수 있을 뿐만 아니라 독성이 없으므로 상시로 탈없이 복용할 수 있다.Therefore, it is not only toxic, but it can be applied to functional food additives and tobacco additives as well as to reduce immunity and defense ability due to the widespread contamination of various harmful substances that are very problematic in modern society. Can be taken without mask.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060125361A KR100812968B1 (en) | 2006-12-11 | 2006-12-11 | A study of purifying hunman inner body with natural herbal plants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060125361A KR100812968B1 (en) | 2006-12-11 | 2006-12-11 | A study of purifying hunman inner body with natural herbal plants |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100812968B1 true KR100812968B1 (en) | 2008-03-11 |
Family
ID=39398646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060125361A KR100812968B1 (en) | 2006-12-11 | 2006-12-11 | A study of purifying hunman inner body with natural herbal plants |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100812968B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697916A (en) * | 2012-06-18 | 2012-10-03 | 龚兆春 | Medicine for alleviating hangover |
KR20150067597A (en) * | 2013-12-10 | 2015-06-18 | 동의대학교 산학협력단 | Maximowiczia Chinensis Extracts For improvement Of Muscel Antioxidant Activity And Manufacturing Method of thereof |
KR101664810B1 (en) * | 2015-11-18 | 2016-10-12 | 케이덴티 주식회사 | Oral composition and manufacturing method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010001582A (en) * | 1999-06-07 | 2001-01-05 | 안철희 | Method for manufacturing a medicine for nonsmoking using a chinese medicine |
KR20020069032A (en) * | 2001-02-22 | 2002-08-29 | 박종숙 | Stop smoking |
KR20050024884A (en) * | 2003-09-05 | 2005-03-11 | 김현석 | An oriental herb extracts composition having detoxification effect on the nicotine and dioxin |
KR20050113091A (en) * | 2004-05-28 | 2005-12-01 | 주식회사 아이엠베스트 | A composition of plants extracts having detoxication ability of toxic ingredients caused by smoking |
KR20060033345A (en) * | 2004-10-15 | 2006-04-19 | 나노바이오메드주식회사 | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same |
-
2006
- 2006-12-11 KR KR1020060125361A patent/KR100812968B1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010001582A (en) * | 1999-06-07 | 2001-01-05 | 안철희 | Method for manufacturing a medicine for nonsmoking using a chinese medicine |
KR20020069032A (en) * | 2001-02-22 | 2002-08-29 | 박종숙 | Stop smoking |
KR20050024884A (en) * | 2003-09-05 | 2005-03-11 | 김현석 | An oriental herb extracts composition having detoxification effect on the nicotine and dioxin |
KR20050113091A (en) * | 2004-05-28 | 2005-12-01 | 주식회사 아이엠베스트 | A composition of plants extracts having detoxication ability of toxic ingredients caused by smoking |
KR20060033345A (en) * | 2004-10-15 | 2006-04-19 | 나노바이오메드주식회사 | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697916A (en) * | 2012-06-18 | 2012-10-03 | 龚兆春 | Medicine for alleviating hangover |
KR20150067597A (en) * | 2013-12-10 | 2015-06-18 | 동의대학교 산학협력단 | Maximowiczia Chinensis Extracts For improvement Of Muscel Antioxidant Activity And Manufacturing Method of thereof |
KR101616170B1 (en) | 2013-12-10 | 2016-04-27 | 동의대학교 산학협력단 | Maximowiczia Chinensis Extracts For improvement Of Muscel Antioxidant Activity And Manufacturing Method of thereof |
KR101664810B1 (en) * | 2015-11-18 | 2016-10-12 | 케이덴티 주식회사 | Oral composition and manufacturing method thereof |
WO2017086653A1 (en) * | 2015-11-18 | 2017-05-26 | 케이덴티 주식회사 | Oral composition and method for preparing same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Panda | Handbook on medicinal herbs with uses: medicinal plant farming, most profitable medicinal plants in India, medicinal plants farming in India, plants used in herbalism, medicinal herbs you can grow, medicinal herbs and their uses, medicinal herbs, herbal & medicinal plants, growing medicinal herb, most profitable medicinal herbs growing with small investment, herbal medicine herbs | |
Adedapo et al. | Comparison of the nutritive value and biological activities of the acetone, methanol and water extracts of the leaves of Bidens pilosa and Chenopodium album | |
Okwu et al. | Evaluation of the chemical composition of Dacryodes edulis and Raphia hookeri Mann and Wendl exudates used in herbal medicine in south eastern Nigeria | |
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
KR20120107557A (en) | Rice bran fermentation extracts with chlorophyll and the manufacturing method thereof | |
Jain et al. | Diverse application of Phoenix sylvestris: A potential herb | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR100823978B1 (en) | Herb extract for removing harmful elements accumulated in a human body and manufacturing method of the same | |
KR100812968B1 (en) | A study of purifying hunman inner body with natural herbal plants | |
WO2002066041A1 (en) | Natural composition | |
KR100406158B1 (en) | The human body a poisonous toxic substance eliminate waste matter from the system natural product a manufacturing process | |
KR100891914B1 (en) | The method of preparing the functional food for diet using extrative extrated from madicin-matrrials of plants | |
Khursheed et al. | Phytochemical and pharmacological investigations on adhatoda zeylanica (medic.): A review | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR101045279B1 (en) | Composition of functional food with weight loss effect | |
KR101470603B1 (en) | Manufacturing method of herbextract for removing harmful elements caused by smoking | |
KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
KR100638573B1 (en) | A composition of plants extracts having detoxication ability of toxic ingredients caused by smoking | |
KR20130029284A (en) | Composition of healthy foods for treatment of dementia | |
KR100761552B1 (en) | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same | |
KR100553576B1 (en) | Functional healthy cadence good stuffs and manufacturing method thereof | |
JP4776474B2 (en) | Herbal medicine composition | |
Hafeez et al. | Evaluation of Biological Characteristics of Abelmoschus esculentus | |
CN111184809A (en) | Food, health-care product or medicine composition for clearing and moistening throat and preparation method thereof | |
Khan | NUTRITIONAL COMPOSITION, PHYTOCHEMICAL AND ANTIOXIDANT ACTIVITY OF STEM OF (Nymphaea nouchali) AND (Nymphaea rubra |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20101223 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140302 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150105 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |